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Growth factors participating in a variety of biological processes have great potential in 
regenerative medicine. However, unprotected growth factors degrade quickly and have little 
efficacy at tissue repair. Delivery of growth factors with different vehicles has been examined to 
prolong the half-lives of growth factors and therefore increase its therapeutic efficacy. After 
decades of research, controlled delivery of growth factor still faces some significant limitations, 
and none has reached clinical translation. 
Heparin, a highly sulfated macromolecule, is used as an anticoagulant clinically. In 
addition, it has high affinity to a large number of biomolecules, including many growth factors. 
The interaction between heparin and heparin-binding growth factors is known to adjust their 
conformation, protect them from proteolytic degradation and regulate their activities. 
Incorporation of heparin in growth factor delivery is consequently a strategy to potentiate the 
bioactivity of growth factors. Currently, most approaches used to immobilize heparin on the 
delivery vehicles rely on covalent modification of heparin that may alter its inherent properties. 
To maximize the efficacy of heparin, we developed a coacervate-based delivery platform in 
which heparin is utilized to complex with a polycation without any modification. The polycation 
neutralizes the negative charges of heparin and precipitates it out of solution. This approach 
allows spatiotemporal control of the release of heparin-binding growth factors. This dissertation 
covers the design, production, characterization and application of heparin-based coacervate in 
controlled release of growth factors. 
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1.0      BACKGROUND 
1.1      CARDIOVASCULAR DISEASE 
Despite decades of efforts on prevention and treatment, cardiovascular diseases (CVD) 
are still the leading cause of death in the US and other developed countries. The latest statistics 
from the American Heart Association highlights the morbidity and mortality of CVD [1]:  
• An estimated 82,600,000 American adults (≥20 years old) have 1 or more types of CVD. 
• CVD caused 813,804 of all 2,243,712 deaths (33.6%) or 1 of every 2.9 death in 2007. 
Each day, more than 2200 Americans died from CVD. The death rate of CVD patients 
was 251.2 per 100,000 (0.251%).  
• Coronary heart disease caused ≈1 of every 6 deaths in 2007. It was estimated that 
785,000 Americans had a new heart attack, 470,000 had a recurrent attack. Totally, 
16,300,000 Americans had coronary heart disease including 7,900,000 had heart and 
9,000,000 had chest pain. 
• Stroke caused ≈1 of every 18 death in 2007. It was estimated that 610,000 Americans 
had a new stroke and 185,000 had a recurrent stroke. Totally, 5,700,000 Americans had 
stroke. 
• 5,700,000 Americans had heart failure. 
• 650,000 to 1,300,000 Americans had congenital cardiovascular defect. 
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The risk factors of CVD including hypertension, smoking, high cholesterol, diabetes and 
obesity are still prevalent in the US: 
• 76,400,000 (33.5%) of US adults have hypertension (systolic pressure ≥140 mmHg 
and/or diastolic pressure ≥90 mmHg). 
• Among Americans ≥18 years old, 23.1% of men and 18.3% of women are smokers. 
• 33,600,000 of US adults have high serum cholesterol (≥240 mg/dL). 
• 18,300,000 Americans had been diagnosed diabetes. 
• 149,300,000 Americans are overweight and obese. 
The cost of health care and treatment for CVD patients is extremely high: 
• The total number of cardiovascular operations and procedures rose from 5,382,000 in 
1997 to 6,846,000 in 2007 (27% increase). 
• The direct and indirect cost of CVD was estimated to be 286 billion dollars in 2007. The 
amount is higher than the 228 billion dollars spent on cancer and benign neoplasms. 
Current diagnosis for CVD relies mostly on physical examination, electrocardiogram 
(EKG), echocardiography (ECG) and blood test. Treatment depending on severity of the 
disease includes medication and surgery (Table 1) [2]. 
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Table 1. Current treatment of CVD 
Cardiovascular disease  Treatment 
Heart valve problems Medication 
Heart valve surgery 
Arrhythmia Medication 
Pacemaker 
Cardiac defibrillation 
Heart attack Medications-clotbusters (should be administered as soon 
as possible for certain types of heart attacks) 
Coronary angioplasty 
Coronary artery bypass graft surgery  
Stroke Medications-clotbusters (must be administered within 3 
hours from onset of stroke symptoms for certain types of 
strokes) 
Carotid endarterctomy 
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1.2       THERAPEUTIC ANGIOGENESIS 
There are two processes that lead to new blood vessel formation, vasculogenesis and 
angiogenesis. Blood vessel formation in early development is termed vasculogenesis, initiated 
by mesodermal stem cells which differentiate in situ to angioblasts and then to endothelial cells. 
Angiogenesis is a highly coordinated process that requires many associated cells and signals to 
complete. Insufficient vascularization leads to ischemic conditions which inhibit tissue growth or 
survival whereas abnormal angiogenesis can promote tumor progression or other diseases 
such as macular degeneration. Following vasculogenesis, angiogenesis is a process which 
includes sprouting and intussusceptive growth of pre-existing blood vessels and subsequent 
remodeling and maturation to form new vasculature [3]. Developing vasculature requires signals 
to induce vessel stabilization to prevent nascent vessels from becoming leaky or nonfunctional 
and subsequent regression back to their original state. Unlike vasculogenesis which happens 
primarily during the embryonic stage, angiogenesis occurs frequently during adulthood. As long 
as there are active vessels, new vasculature can be generated following biophysical and 
physiological cues in the environment, of which the most highly studied are angiogenic factors. 
Notable angiogenic factors include vascular endothelial growth factor (VEGF), angiopoietin, 
transforming growth factor, fibroblast growth factor (FGF), hepatocyte growth factor, and 
platelet-derived growth factor, although dozens of other proteins are also known to participate in 
blood vessel formation. The importance of several angiogenic factors has been revealed by 
gene knockout resulting in embryonic lethality [4,5]. 
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Under normal physical conditions, most secretory growth factors are associated with 
components of the extracellular matrix (ECM) including heparan sulfate proteoglycan and 
fibronectin [6]. Physiological fluctuations such as insufficient nutrients and low oxygen 
concentration (hypoxia) induce the release of proangiogenic factors via cleavage of ECM by 
hydrolytic enzymes. A chemical gradient is created as released factors diffuse away in the 
surrounding tissue. Several downstream angiogenic processes are driven by this gradient 
including activation of additional angiogenic genes, proteolytic degradation of the ECM, 
proliferation and migration of endothelial cells to form tubes, and recruitment of mural cells that 
stabilize the nascent vessels. 
Jeffery M. Isner  pioneered the concept of therapeutic angiogenesis decades ago led by 
[7]. His seminal work observing revascularization in response to VEGF injection in a hindlimb 
ischemia model demonstrated that single factor administration can be adequate to generate 
functional blood vessels. Subsequently, several other angiogenic factors have also been utilized 
alone or combined to promote angiogenesis. Contrary to cancer treatment where drugs are 
selected to inhibit blood vessel growth, angiogenic therapy aims to develop neovasculature 
through various strategies. Therapeutic angiogenesis has been widely examined for treatment 
of many human diseases. Treatment of cardiovascular disorders, which incur high mortality and 
morbidity in developed countries, could be significantly improved with successful therapeutic 
angiogenesis. Other processes such as wound healing and organ repair and regeneration also 
depend on a sufficient blood supply. Unfortunately, there is no FDA-approved drug or device 
that can induce angiogenesis efficiently. 
Therapeutic angiogenesis includes gene delivery, protein delivery and cell delivery. 
Gene delivery has the advantage of high protein production efficiency, essentially providing a 
sustained source of protein release. Furthermore, genes carried by viral vectors such as adeno-
associated virus, lentivirus and retrovirus are integrated into the host chromosome, resulting in 
expression of angiogenic genes even after cell division. However, this is not always desirable, 
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as over-production of a certain angiogenic factor could inhibit blood vessel formation which 
requires a precise balance between different signals. One prior study revealed that unregulated 
over-production of VEGF in the myocardium caused heart failure and vascular tumor formation 
[8]. Viral vectors, which are the most effective vehicle to transfer genes, can also trigger 
immune responses against viral components [9]. Other gene transfer methods using non-viral 
vectors such as ultrasound and electric field are less efficient and require much investigation 
[10,11]. Several Phase-III clinical trials of angiogenic gene delivery to treat human 
cardiovascular diseases have been conducted but the results are mostly discouraging [12]. 
Protein delivery is the most straightforward strategy for therapeutic angiogenesis. Blood 
vessel formation is induced by simple injection of angiogenic proteins, with the extent of 
angiogenesis being controlled by dosage and duration of release. Compared to gene- and cell-
based therapies, protein delivery is thought of as an “off-the-shelf” treatment. Protein can be 
manufactured and shipped in lyophilized form, reconstituted in buffer and applied immediately. 
Production and purification of angiogenic proteins is well established, and the cost is relatively 
low. All of these factors contribute to the advantages of angiogenic protein therapy. 
Nevertheless, maintaining angiogenic activity at a specific site of interest is a significant 
challenge. Angiogenic protein, like viral vectors or cells, can be delivered either systematically 
or locally. Systematic administration, such as intravenous or intraperitoneal injection, is 
performed easily but is inefficient at targeting a desired tissue and most of injected protein is 
rapidly cleared by the mononuclear phagocyte system [13]. Only a small fraction reaches the 
desired region, so high dosage and repeated injection of angiogenic factors is required [14]. 
Local administration such as intracoronary, intramyocardial or intracerebral injection can better 
confine the distribution of the protein but usually requires a special device or highly invasive 
surgery [15]. 
Cell-based therapy is another active field that is drawing a lot of attention. Compared to 
single factor therapies, therapeutic angiogenesis via cell therapy is believed to have a more 
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comprehensive and extensive effect. Cell selection is based on the capability of the candidate 
cells to differentiate into blood vessel-associated cells or secrete proangiogenic factors. Several 
stem/progenitor cells such as bone marrow cells and endothelial progenitor cells had been 
identified, isolated and applied in clinical trials with myocardial infarction patients [16]. The 
results indicate multiple benefits highlighted by improved blood perfusion and cardiac function. 
However, acquiring enough cells, on the order of millions per patient, is a significant challenge 
and their in vivo viability is usually very low. Most cells fail to integrate with the host tissue and 
die soon after delivery. In recent years, induced pluripotent stem cells (iPS), generated by 
activating key transcriptional factors, provide an attractive avenue for cell therapy [17]. The 
beauty of this technique is that terminally differentiated cells can be reprogrammed back to an 
embryonic-like state and then differentiated to a desired cell type under specific culture 
conditions [18]. Autologous cells are used which avoids many difficulties such as limited cell 
sources and immune rejection. However, the most effective way to achieve pluripotency is 
based on viral vectors that carry similar safety concerns to gene therapy. As a very young 
technology, iPS therapy still requires significant investigation followed by validation in clinical 
trials before its potential can be accurately evaluated [19]. 
In many cases delivery of angiogenic factors targets ischemic tissue that is intrinsically 
different from normal tissue [20,21]. For example, ischemia causes hypoxic conditions that shift 
glucose metabolism from aerobic to anaerobic. Hence, the production of lactic acid is greatly 
increased and results in acidosis which reduces pH value down to approximate 6.5, significantly 
lower than the normal value of approximate 7.4 [22]. In addition, ischemia is often accompanied 
by intense inflammatory responses including infiltration of neutrophils and macrophages and 
secretion of reactive oxygen species and hydrolytic enzymes to the local region [23]. Lysosomal 
enzymes released from the necrotic tissue could degrade surrounding proteins. Furthermore, a 
new study found that the rapid development of microvasculature accompanying inflammation is 
not necessarily favorable and could trigger a refractory mechanism to clear angiogenic factors 
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[24]. All of these elements constitute a harsh environment that makes the bioactivity of delivered 
angiogenic factors difficult to maintain. 
Among all angiogenic factors, VEGF is believed to be the most important modulator 
involved in all steps of vasculature formation [25]. The human VEGF family is comprised of 5 
members including VEGF (VEGF-A, vascular permeability factor), VEGF-B, VEGF-C, VEGF-D 
and placenta growth factor. Generated by alternative splicing, VEGF-A has 5 isoforms, amongst 
which VEGF121 and VEGF165 are predominant. All isoforms except VEGF121 contain heparan 
sulfate binding domains; their bioactivity is therefore localized and reliant on the presence of 
heparan sulfate [26, 27]. All VEGF isoforms bind to VEGF receptor-1 (VEGFR-1, a.k.a Flt-1) 
and VEGF receptor-2 (VEGFR-2, a.k.a Flk-1 and KDR), which are receptor tyrosine kinases 
(Table 2) [28]. The activation of VEGFR results in phosphorylation and dimerization of the 
receptor. Downstream signaling is diverse and includes MAPK, PI3K and PLC-γ pathways. 
VEGF165 and other high molecular weight isoforms also bind to neuropilin-1, which serves as a 
co-receptor that enhances VEGF-VEGFR interaction and alters VEGF signaling [29,30]. 
Endothelium is the major tissue that expresses both VEGFR-1 and VEGFR-2 and consequently 
processes such as proliferation and survival of endothelium is highly regulated by VEGF. For 
therapeutic purposes, local VEGF levels have been upregulated by gene, protein, and cell 
therapy. Thus far, vegf gene delivery has comprised the majority of clinical trials [31]. In some 
trials, significant neovasculature formation and increased blood perfusion were observed 
[32,33]. On the other hand, several studies concluded that VEGF expression has to be very 
tightly regulated in order to avoid side effects [34,35]. Animal studies have further confirmed 
that stable and functional vessel growth requires a high degree of control over VEGF production 
[36]. Future efforts in VEGF gene or protein therapeutic strategies will be required to achieve 
this goal.   
Another potent and widely employed angiogenic factor is FGF. FGFs are expressed in 
diverse organisms from nematodes to vertebrates. In vertebrates, 22 FGFs with 30-70% amino 
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acid sequence homology, bind selectively to 4 major receptors: FGFR1b/c, FGFR2b/c, 
FGFR3b/c and FGFR4 [37,38]. Direct comparison of amino acid sequences suggests that FGFs 
share conserved sequences in the primary FGFR binding site but differ in the secondary site, 
resulting in the selectivity between FGFRs [39]. FGFR is also a receptor tyrosine kinase and its 
activation induces phosphorylation and dimerization. Similar to VEGF, downstream signaling 
pathways include MAPK, PI3K and PLC-γ which control both genotype and phenotype. It is 
worth noting that heparan sulfate binds to all FGF-FGFR complexes and potentiates the FGF 
signal transduction. The FGF pathway participates in many biological processes including 
embryonic development [40], wound healing [41], angiogenesis [42] and tumorigenesis and is 
thus regarded as one of the most pleiotrophic factors. Specifically in angiogenesis, it is well 
known that the effects of FGFs include migration [43], proliferation [44,45], differentiation and 
survival of blood vessel-associated cells. Recent studies also show that the integrity of the 
vasculature is highly regulated by FGF signaling. When FGF signaling is inhibited, endothelial 
junctions become compromised resulting in increased vessel permeability [46]. FGF signaling is 
also capable of controlling other angiogenic factor pathways, especially VEGF. This is evident 
because sustained stimulation by FGF is required to maintain VEGFR expression in the 
endothelium [47]. 
Among all FGF members, FGF2 is the most extensively studied and most often utilized 
in therapeutic angiogenesis. Multiple animal studies have demonstrated the potential of 
controlled delivery of FGF2 alone or combined with other factors in treating ischemic diseases 
[48,49]. So far, a few FGF2 phase-I human trials have been conducted in myocardial infarction 
patients. No obvious toxicity was observed when high dosage of FGF2 was administered by 
intracoronary delivery, verifying that these levels of FGF2 are safe in humans [50,51]. However, 
long-term benefit was not observed, possibly due to insufficient activity of FGF2 in the human 
body [52,53]. 
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Besides FGF2, other FGF members also can initiate angiogenesis and may be 
successful therapeutics. For example, fgf4 and fgf5 are two angiogenic genes that have been 
delivered via adenovirus at the embryonic stage for treating coronary heart diseases [54,55]. 
FGF9, in contrast to FGF2 that affects both endothelium and mesenchyme, is known to 
primarily target mesenchyme. Developmental studies suggest that FGF9 induces vegfa 
expression in lung mesenchyme and is necessary for capillary formation [56]. Another study 
elucidates the upregulation of FGF9 during the maturation of the smooth muscle layer which 
controls the survival and physiological response of the vasculature [57].  Superior to FGF2 
alone, co-delivery of FGF2 and FGF9 in growth factor-depleted matrigel generates blood 
vessels of larger diameter and with thicker smooth muscle layers. 
Although FGF members share conserved amino acid sequences, the expression pattern 
and functions of each are still distinctive. Current knowledge of FGFs was mainly accumulated 
by gene knockout studies which are not able to detect events at molecular level (Table 3). 
Consequently, the biological roles of many FGFs require further investigation to decipher. It is 
highly possible that more FGFs or FGF combinations will possibly be utilized in future 
therapeutics. 
Besides VEGF and FGF, other angiogenic factors have also been intensely investigated. 
Angiopoietin-1, which binds to the Tie2 receptor, is able to balance the effects of VEGF and 
enhance vasculature stability and its efficacy has been demonstrated in animal studies [58,59]. 
Hepatocyte growth factor, which stimulates endothelial cell proliferation, can potentiate the 
mitogenic activity of VEGF and increase VEGF production [60]. It has also been shown to 
promote secretion of proteases that are involved in ECM degradation and cell migration [61]. 
Granulocyte colony-stimulating factor acts primarily as a cytokine to mobilize progenitor cells 
from the bone marrow and has been demonstrated to recruit CD34-positive cells to the infarct 
area and improve ventricular function in a clinical study [62]. However, its overall effect is still 
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debated [63]. Other angiogenic factors such as insulin-like growth factor, erythropoietin and 
stem cell factor have also been investigated in clinical trials [64].  
Another group of proteins drawing significant attention in therapeutic angiogenesis are 
morphogens such as Sonic hedgehog[65] , Notch [66] and Wnt [67]. The effects of morphogens 
are thought to be more comprehensive because they can regulate transcriptional upregulation 
of myriad pathways. However, their mechanisms in blood vessel development have to be better 
understood before clinical trials can be justified. 
Blood vessels that carry oxygen, nutrients and signals are critical in both developmental 
and adult physiology. Induction of neovasculature has the potential to treat many human 
diseases. No matter which approach is used, angiogenic activity has to be maintained and 
precisely controlled in order to achieve stable vascularization. In addition to further 
understanding of angiogenic factors, improvements in delivery strategies will be critical for the 
success of therapeutic angiogenesis. 
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Table 2. VEGF family and function 
 Major receptor Function 
VEGF VEGFR-1; VEGFR-2 ; neuropilin  Vasculogenesis; 
Angiogenesis 
VEGF-B VEGFR-1 Vasculogenesis; 
Angiogenesis 
VEGF-C VEGFR-3 (Flk-4) Lymphangiogenesis 
VEGF-D VEGFR-3 Lymphangiogenesis 
Placenta growth 
factor 
VEGFR-1 Angiogenesis 
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Table 3. FGF family and function  
 Phenotype of knockout mouse Physiological role 
FGF1 Normal Not established 
FGF2 Loss of vascular tone; Slight loss of cortex neurons Not established 
FGF3 Inner ear agenesis in humans Inner ear development 
FGF4 Embryonic lethal Cardiac valve leaflet formation; Limb development 
FGF5 Abnormally long hair Hair growth cycle regulation 
FGF6 Defective muscle regeneration Myogenesis 
FGF7 Matted hair; Reduced nephron branching in kidney Branching morphogenesis 
FGF8 Embryonic lethal Brain, eye, ear and limb development 
FGF9 Postnatal death; Gender reversal; Lung hypoplasia Gonadal development; Organogenesis 
FGF10 Failed limb and lung development Branching morphogenesis 
FGF16 Embryonic lethal Heart development 
FGF17 Abnormal brain development Cerebral and cerebellar development 
FGF18 Delayed long-bone ossification Bone development 
FGF19 Increased bile acid pool Bile acid homeostasis; Lipolysis; Gall bladder filling 
FGF20 No knockout model Neurotrophic factor 
FGF21 No knockout model 
Fasting response; Glucose 
homeostasis; Lipolysis and 
lipogenesis 
FGF22 No knockout model Presynaptic neural organizer 
FGF23 Hyperphosphataemia; Hypoglycaemia; Immature sexual 
organs 
Phosphate homeostasis; 
Vitamin D homeostasis 
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2.0     SPECIFIC AIMS 
Growth factors participating in a variety of biological processes have great potential to be 
applied in regenerative medicine. However, unless protected, free growth factors are degraded 
quickly by proteases and therefore have little efficacy at tissue repair. Delivery of growth factors 
with different vehicles has been examined to prolong the half-lives of growth factors and 
therefore potentiate the bioactivity of growth factors. Even after decades of effort, existing 
vehicles for growth factor delivery still have some limitations that need to be overcome. 
Heparin, a highly sulfated macromolecule, is used as an anticoagulant in clinical 
treatment. In addition, it has high affinity to a large number of biomolecules including many 
growth factors. The interaction between heparin and heparin-binding growth factors is known to 
adjust their conformation, protect them from proteolytic degradation and regulate their activities. 
Incorporation of heparin in growth factor delivery is consequently a strategy to potentiate the 
bioactivity of growth factors. Currently, most approaches used to immobilize heparin on the 
delivery vehicles rely on the covalent modification of heparin that may alter its inherent 
properties. To maximize the efficacy of heparin, we have developed a coacervate-based 
delivery platform in which heparin is utilized to complex with a polycation without any 
modification. The polycation neutralizes the negative charges of heparin and precipitates it out 
of solution. The spatiotemporal properties of heparin and heparin-binding growth factors are 
expected to be controlled through this approach. To give a comprehensive evaluation of this 
delivery platform in translational medicine, this thesis covers the below aspects from the 
invention to its application: 
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Specific aim 1: Development of a coacervate-based platform for growth factor delivery 
We introduced a coacervate-based platform containing heparin and a novel polycation, 
poly(ethylene argininylaspartate diglyceride) (PEAD). PEAD, composed of arginine, aspartate, 
and diglyceride moieties was synthesized through a polycondensation reaction followed by a 
coupling reaction. The backbone of this polycation contained ester bonds and was therefore 
expected to be hydrolyzable. The biocompatibility of PEAD was evaluated via in vitro and in vivo 
assays and compared with a widely used polycation, polyethyleneimine. The characterization of 
the [PEAD:heparin] coacervate includes several physical methods. Its potential to be applied as 
a delivery vehicle was evaluated by determining the load efficiency and release profiles of 
heparin-binding growth factors. Lastly, the bioactivity of the delivered growth factors was 
compared with the free-form growth factors using cell-based assays.  
Specific aim 2: Therapeutic angiogenesis via FGF2 coacervate 
Therapeutic angiogenesis via growth factor delivery has potential in treatment of many 
human diseases, especially cardiovascular-related. However, due to the insufficient bioactivity 
of the delivered factors, the nascent blood vessels do not have sufficient stability and regress 
over time. I evaluated the ability of [PEAD:heparin] coacervates to deliver an angiogenic factor 
and examine the responses in vivo by two approaches.  
Sub-aim 2.1: In vivo angiogenic activity of [PEAD:heparin:FGF2].  
In a rodent model, we subcutaneously injected fibroblast growth factor-2 (FGF2) 
containing coacervate and observed long term angiogenesis. FGF2, a potent angiogenic factor, 
has the ability to induce the proliferation of endothelial cells, similar to vascular endothelial 
growth factor. In addition, FGF2 has ability to stimulate mural cells to associate and stabilize the 
endothelial tubes. I anticipated that if the bioactivity of FGF2 was well preserved, mature blood 
vessels will be generated even at low dosage of applied FGF2. For comparison, the hemoglobin 
concentration at the injection site will be measured. The expression of associated markers will 
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be evaluated to determine the maturity of neovasculature. I expected that the [PEAD:heparin] 
coacervate effectively enhance the bioactivity of FGF2. 
Sub-aim 2.2: Post-myocardial infarction recovery promoted by [PEAD:heparin:FGF2].  
Ischemia induced by myocardial infarction (MI) causes short blood supply locally and 
compromises contractile function. Further examining this coacervate-based delivery platform to 
promote angiogenesis, I determined its efficacy in a MI model. Successful angiogenesis imparts 
functional recovery that was assessed by echocardiography. In addition, histological staining 
was used for observation of gross appearance and fibrosis. Immunohistochemistry was utilized 
to study angiogenesis, the integrity of myocardium and the inflammatory responses.  
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3.0     DESIGN OF A PLATFORM FOR GROWTH FACTOR DELIVERY 
The FGF family is well known for its high affinity to heparin which modulates the 
interaction between FGFs and their receptors. As revealed by the crystal structure (Fig. 1 left), 
the heavily anionic heparin brings the cationic sequences on FGF and its receptor closely 
together and stabilizes the ternary complex largely through polyvalent ionic interactions [68]. In 
order to mimic the interactions between these three components, a synthetic polycation was 
applied to substitute the heparin-binding sequence of the FGF receptor and form a ternary 
complex containing the polycation, heparin and FGF (Fig. 1 right). The addition of a polycation 
neutralized the excess negative charge of heparin and immediately induced formation of 
[polycation:heparin:heparin-FGF] coacervates. This approach was expected to anchor the 
heparin-binding factor and enabled its controlled release. Charge interaction between the 
polycation and heparin was utilized instead of covalent modification of heparin in an effort to 
minimize the perturbation of the functions of heparin.  
Most existing polycations have low biocompatibility. A novel polycation, poly(ethylene 
argininylaspartate diglyceride) (PEAD), was consequently designed and used to form 
[PEAD:heparin] coacervate. PEAD, composed of arginine, aspartate, and diglyceride moieties 
was synthesized through a polycondensation reaction followed by a coupling reaction. The 
backbone of this polycation contained ester bonds and was therefore expected to be 
hydrolyzable. The biocompatibility of PEAD was evaluated via in vitro and in vivo assays and 
compared with a widely used polycation, polyethyleneimine. The characterization of the 
[PEAD:heparin] coacervate included several physical methods. Its potential to be applied as a 
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delivery vehicle was evaluated by determining the load efficiency and release profiles of 
heparin-binding growth factors. Lastly, the bioactivity of the delivered growth factors was 
compared with the free-form growth factors using cell-based assays. 
 
Figure 1. Design of a coacervate delivery matrix. The crystal structure of [FGF:heparin:FGFR] 
complex indicates that heparin actively participate in the interaction of FGF and its receptor 
whose heparin-binding domains are labeled yellow and pink, respectively (left). The top right 
scheme represents the design of the coacervate where a synthetic polycation replaces the 
heparin-binding domain of FGFR and forms a complex with heparin and FGF. 
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3.1      SYNTHESIS OF A BIOCOMPATIBLE POLYCATION 
Polycations are very useful in biotechnology. However, most existing polycations have 
high toxicity that significantly limits their clinical translation. Our laboratory designed 
poly(ethylene argininylaspartate diglyceride) (PEAD) that is based on arginine, aspartic acid, 
glycerol, and ethylene glycol. A set of in vitro assays demonstrated that PEAD exhibited no 
cytotoxicity at 1 mg/ml, which is at least 100 times higher than the widely used polycation- 
polyethylenimine (PEI). Subcutaneous injection of 1 mg PEAD in rats did not cause an adverse 
response acutely or after 4 weeks. Zeta potential measurements revealed that PEAD has high 
affinity to biological polyanions such as DNA and hyaluronic acid (HA). This polycation 
represents a new platform of biocompatible polycations that may lead to clinical innovations in 
gene therapy, controlled release, tissue engineering, biosensors, and medical devices. 
 
 
 
 
3.1.1      Introduction 
Self-assembly of polycations and polyanions can generate complexes with distinct 
physical and chemical properties. It is a highly active field of research in recent years 
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[69,70,71]. Polycations such as poly-L lysine (PLL), polyethylenimine (PEI) and chitosan have 
strong interactions with biological polyanions. This interaction can be used to form a nonviral 
vector for gene therapy [72] a drug delivery vehicle with controlled-release capability [73,74], 
and layer-by-layer assembly of thin films with unique properties [75,76]. Furthermore, 
polycations have been used as coatings to enhance cell attachment [77], tools to separate 
membrane proteins [78,79,80]  and reagents to eradicate microbes [81,82,83]. Despite this 
diverse range of applications, high toxicity to mammalian cells hinders further biomedical 
development of polycations [84,85,86,87,88,89,90]. Consequently, there is significant interest 
in improving the biocompatibility of polycations [91,92,93,94]. 
Our laboratory has previously reported a polycation, poly(L-argininate glyceryl succinate) 
with high biocompatibility and utility in controlled release of heparin-binding growth factors 
[95,96]. However, the synthesis of poly(L-argininate glyceryl succinate) is time consuming. This 
may compromise its potential adoption in translational research. Thus, a new polycation was 
designed with the same design principle but the production was simplified. Poly(ethylene 
argininylaspartate diglyceride) (PEAD) was made from commercially available starting materials 
in 2 steps. In vitro and in vivo tests demonstrated that PEAD had much higher biocompatibility 
than PEI. PEAD has high affinity to biological polyanions, which makes it potentially very useful 
in biomedical applications. 
 
3.1.2      Experimental section 
Materials 
Nα-Boc-L-aspartic acid (t-BOC aspartic acid), Nα-Boc-L-arginine (t-BOC arginine) (EMD 
Chemicals, Gibbstown, NJ), ethylene glycol diglycidyl ether (EGDE), trifluoroacetic acid (TFA) 
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(TCI America, Portland, OR), anhydrous 1,4-dioxane, dimethylforamide (DMF) and tetra-n-
butylammonium bromide (TBAB) (Acros organics, Geel, Belgium), dicyclohexylcarbodiimide 
(DCC, stored in N2 glovebox), N-hydroxysuccinimide (NHS) (Alfa Aesar, Ward Hill, MA) and 4-
dimethylaminopyridine (DMAP) (Avocado Research Chemicals Ltd, Lancaster, UK) were used 
without further purification. Polyethyleneimine (PEI) MW ~ 25,000 (Polysciences, Warrington, 
PA), Potassium hyaluronate (EMD Chemicals, Gibbstown, NJ) and plasmid pEYFP-N1 (4.7Kb) 
(Clontech, Mountain View, CA) were used as received. 
Synthesis of PEAD 
The polymerization of EGDE and t-BOC aspartic acid was performed as previously 
reported [97,98,99]. Briefly, EGDE (1.306 g, 7.5 mmol) was mixed with t-BOC aspartic acid 
(1.749 g, 7.5 mmol) and TBAB (5 mg, 0.016 mmol). 2 ml of 1,4-dioxane or DMF were added to 
the mixture and the reaction mixture was heated to 100 °C and maintained  under N2 for 48 h. 
The solvent was evaporated at reduced pressure followed by extraction of TBAB using 
deionized water and precipitation of the product in excess diethyl ether. The precipitation was 
repeated twice until no impurity peaks were observed in the 1H NMR spectrum. The t-BOC 
protective group on the aspartate was removed with 1:4 TFA:dichloromethane solution (20 ml) 
for 2 h at room temperature to obtain the intermediate, poly(ethylene aspartate diglyceride) 
(PED). 
Conjugation of t-BOC arginine to PED was performed by DCC/NHS coupling. Briefly, t-
BOC arginine (625 mg, 2.28 mmol), DCC (611 mg, 2.96 mmol), NHS (262 mg, 2.28 mmol) and 
DMAP (5 mg, 0.041 mmol) were dissolved in DMF and reacted for 10 min followed by the 
addition of PED (700 mg, 2.28 mmol). The mixture was stirred under N2 for 24 h. The insoluble 
dicyclohexylurea was removed by filtration. After most DMF was removed by evaporation at 
reduced pressure, the solution was added dropwise into 15 ml of TFA and stirred for 90 min at 
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ambient temperature to remove the t-BOC group on arginine. TFA was removed by evaporation 
at reduced pressure and the product was precipitated in ethyl acetate followed by hexanes. The 
precipitation was repeated at least twice until no impurity or solvent peaks were observed in the 
1H NMR spectrum. 
Characterization of PEAD 
1H NMR and FTIR spectra were recorded on a Mercury 400 NMR (Varian, Palo Alto, CA) 
and a Nicolet IR-100 spectrometer (Thermo, Waltham, MA), respectively. The molecular weight 
of the polymers was determined by a PL-GPC 50 Plus-RI equipped with a PD 2020 Light 
Scattering Detector and a PL-BV 400RT Viscometer (Varian, Palo Alto, CA). Two MesoPore 
300x7.5 mm columns and DMF containing 0.1 % LiBr were used as stationary and mobile 
phases, respectively. Polylatide-poly(ethylene oxide) (PL-PEO) standards were used for 
calibration and molecular weight calculation. 
The degradation of PEAD was monitored by the variation of light scattering. Briefly, 10 
mg/ml of PEAD in PBS containing 0.5% of FBS was incubated at 37 °C under gentle agitation. 
At day 0, 7, 14, and 30, aliquots were collected for analysis. A Viscoteck VE2100 GPC 
(Malvern, Westborough, MA) equipped with a Suprema 300x8 mm column (Polymer Standards 
Service, RI) and a right angle light scattering detector was used for separation and detection 
respectively. 
In vitro biocompatibility 
NIH 3T3 fibroblasts were cultured in DMEM (Mediatech, Manassas, VA) containing 10 % 
fetal bovine serum (FBS) (Lonza, Walkersville, MD) and 1% penicillin/streptomycin (Lonza, 
Walkersville, MD) and expanded under standard culture conditions at 37 °C with 5% CO2 until 
sufficient quantities were obtained. Human aortic endothelial cells (HAEC) (Lonza, Walkersville, 
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MD) (passage 6-8) were cultured in MCDB 131 medium (Mediatech, Manassas, VA) containing 
10% FBS and 1% penicillin/streptomycin, and supplemented with 1 ng/ml epithelial growth 
factor (EGF), 2 ng/ml basic fibroblast growth factor (FGF2), 2 ng/ml insulin-like growth factor-1 
(IGF1), 1 ng/ml vascular endothelial growth factor (VEGF) and 1 µg/ml hydrocortisone (all 
growth factors were from the same vendor, Sigma-Aldrich, St. Louis, MO). The medium 
including all the supplements is referred to as the complete medium.  
For lactate dehydrogenase (LDH) assay (n=4), 3-(4,5 -dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay (n=4) and live/dead assay (n=4), 5×103 cells per well were 
seeded in 96-well plates one day before the experiment. PED, PEAD or PEI dissolved in the 
complete medium at the desired concentrations (10, 5, 2, 1 mg/ml for PED and PEAD; 10, 1, 
0.1, 0,01 mg/ml for PEI) was added into each well. The complete medium alone was used as 
the control. After 24 h incubation, LDH activity in the culture medium was measured by a 
CytoTox 96® Non-Radioactive Cytotoxicity Assay kit (Promega, Madison, WI). Cell metabolic 
activity was determined by a Vybrant® MTT Cell Proliferation Assay Kit (Invitrogen, Carlsbad, 
CA) according to a modified protocol [100]. The level of capase-3 was measured using an 
EnzChek® Caspase-3 Assay Kit (Invitrogen, Carlsbad, CA). Cell viability was analyzed by using 
a LIVE/DEAD® Viability/Cytotoxicity Kit (Invitrogen, Carlsbad, CA). The absorbance and 
fluorescence were recorded by a SynergyMX plate reader (Biotek, Winooski, VT). 
In vivo biocompatibility 
Male Sprague Dawley rats with an average body weight of 300 g were used and cared 
for in compliance with a protocol approved by the Institutional Animal Care and Use Committee 
of the University of Pittsburgh. Under isoflurane anesthesia, 1 mg of PEAD or PEI in 100 µl 
saline (0.9%) was injected subcutaneously into the back of each animal.  The animals were 
sacrificed at post-injection day 3, 14 and 28. The tissue surrounding the injection site and major 
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organs including lung, liver and kidney were harvested and fixed in 10 % formalin. Cross-
sections (4 µm thick, longitudinal axial cut) were stained with hematoxylin and eosin (H & E) to 
examine inflammation or any adverse effects using an inverted microscope Eclipse Ti (Nikon, 
Melville, NY) equipped with a RETIGA-SRV digital camera (QImaging, BC, Canada).   
Zeta potential and dynamic light scattering (DLS) measurement 
All polymer solutions were prepared at the concentration of 1 mg/ml in deionized water 
and saline respectively.  All zeta potential measurement was carried out in water and DLS was 
performed in both water and saline. For [PEAD:DNA] complex formation, 10 μl of plasmid 
(pEYFP-N1) solution (1 μg/μl) was titrated with different amounts of PEAD solution. 750 μl of 
deionized water or saline was added to dilute the complex before the measurement. For 
[PEAD:HA] complex formation, 100 μl of HA solution (1 mg/ml) was titrated with increasing 
amounts of PEAD solution. 1 ml of deionized water or saline was added for dilution, and 750 μl 
of solution was used for zeta potential and particle size measurement on a Zetasizer Nano ZS 
(Malvern, Westborough, MA). 
Scanning electron microscopy (SEM) 
The SEM samples were prepared by mixing PEAD with DNA (mass ratio of PEAD to 
DNA: 1.5) or hyaluronic acid (mass ratio: 4) to form the complex. The complexes were dropped 
on aluminum stubs, lyophilized, sputtered with gold and viewed with a Leo 1530 SEM (10 kV, 3 
nm spot size) (Carl Zeiss SMT, Peabody, MA). 
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Statistical analysis 
The results of in vitro biocompatibility assays were analyzed by ANOVA with post-hoc 
Bonferroni correction. The value of the control group was compared with that of each PEAD 
concentration individually. A p value < 0.05 was considered significant. 
3.1.3       Results and discussion 
Synthesis and characterization of PEAD 
The synthesis of PEAD starts from a polycondensation reaction between t-BOC aspartic 
acid and EGDE under the catalysis of TBAB. Deprotection of t-BOC formed the intermediate, 
PED, with ~94 % yield. The conjugation of t-BOC arginine to PED and then deprotection of t-
BOC produced PEAD which comprises three parts derived from arginine, aspartate and 
ethylene glycol (Fig. 2). Because removal of DMF by repeated precipitation caused a significant 
loss of PEAD, the yield of the arginine conjugation step is 33 %. Clearly, a more efficient 
purification method needs to be developed to increase the yield in the future.   
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Figure 2. Synthetic routes and chemical structures of PEAD and its intermediate. Poly(ethylene 
aspartate diglyceride), PED, was synthesized by polycondensation of t-BOC aspartic acid and 
EGDE catalyzed by TBAB in DMF or 1,4-dioxane followed by removal of t-BOC in 20 % TFA in 
dichloromethane. PEAD was synthesized by conjugation of t-BOC arginine to the aspartic 
amino group under the activation of DCC, NHS and DMAP followed by deprotection using TFA. 
The chemical shifts in 1H NMR for the key functional groups are marked on the structure. 
 
The structure of the polymer was analyzed using NMR, IR, and GPC. The 1H NMR 
spectrum showed two chemical shifts at 1.7 and 1.9 ppm corresponding to the β and γ 
methylene protons on the arginine moiety (Fig. 3). The chemical shift at 4.1 ppm was from the α 
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hydrogen of the aspartate moiety. The ethylene glycol portion produced a multiplet between 3.4 
to 3.9 ppm. The conversion of deprotected primary amine to arginine was nearly quantitative 
according to NMR integration of arginine proton "c" and the rest of the protons of PEAD. The 
intermediate, PED, had a weight average molecular weight (Mw) of 73,750 Da with a 
polydispersity index (PDI) of 1.18. The polymerization was performed either in DMF or 1,4-
dioxane. 1,4-dioxane yielded polymers with a higher molecular weight and a lower 
polydispersity (Fig. 3). The molecular weight of the intermediate was higher than those of the 
final products because the deprotection of t-BOC by TFA can also cleave the ester bonds of the 
backbone. IR spectrum revealed a clear difference between PED and PEAD. PED had two 
distinct peaks at 1668 and 1733 cm-1 corresponding to the ester bonds in the polymer 
backbone. The guanidine group on arginine increased the intensity of the absorption between 
1635-1670 cm-1 and broadened the absorption between 3000-3500 cm-1 (Fig. 4). 
 
 
 Figure 3. 1H NMR spectrum of PEAD shows proton signals consistent with functional groups 
derived from arginine, aspartate and ethylene glycol. The solvent used in NMR, D2O, has a 
sharp signal at 4.79 ppm. The inset summarizes the GPC result. Polycondensations performed 
in 1,4-dioxane have higher Mw and smaller PDI. 
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Figure 4. FTIR spectrum reveals that PED has strong absorption at 1668 and 1733 cm-1 due to 
the ester bonds connecting EGDE and aspartate (dotted line). PEAD has strong absorption in 
the region (1635-1750 cm-1) and (3000-3500 cm-1) supposedly contributed by the amide bonds 
connecting arginine and aspartate and guanidinium groups of arginine moiety (solid line). 
 
In our previous study, different catalysts and solvents were examined for the same 
polycondensation reaction; it was found that TBAB was a good catalyst, and 1,4-dioxane was 
an appropriate solvent in terms of yield and molecular weight [99]. The monomers used in this 
study were more polar, but the results showed a similar trend with respect to solvent. 
As a polyester, PEAD was expected to be hydrolysable. To test the degradability, PEAD 
was dissolved in PBS containing 0.5% FBS, and the intensity of the scattered light was 
measured at different time points (Fig. 5). The polymer signal was clearly visible after 30 days. 
The steady drop of the intensity of the scattered light suggested that PEAD degraded gradually 
via simple hydrolysis under test conditions.  
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Figure 5. The degradation of PEAD as determined by the change of light scattering with time. 
The intensity of the peak at retention time 5.3 min gradually decreased. This demonstrated that 
PEAD is degradable but the process is slow under the testing conditions. 
Examination fibroblasts and endothelial cytotoxicity 
To study the cytocompatibility of PEAD, in vitro assays were performed using NIH 3T3 
fibroblasts and HAECs. NIH 3T3 fibroblasts were chosen because they have been used 
extensively to test polycation cytocompatibility [101]. Furthermore, HAECs could represent non-
immortalized human cells. In addition to PEAD, the cytocompatibility of the intermediate, PED, 
was also tested. Therefore it was able to estimate the influence of arginine conjugation on 
biocompatibility. The results were all compared with the widely used polycation, PEI. After 
incubation with various concentrations of polycations for 24 h, a series of assays including LDH, 
MTT, caspase-3 activity, and live/dead assays were performed to determine the 
cytocompatibility of PEAD.  
When testing PEAD with NIH 3T3 fibroblasts, LDH assay revealed that 1 mg/ml of PEAD 
did not compromise cell membrane integrity (Fig. 6a). MTT assay showed that 5 mg/ml did not 
reduce cellular metabolism. There was no activation of caspase-3 at any of the concentrations 
tested. Live/dead assay showed that 5 mg/ml of PEAD had no impact on the ratio of live to dead 
cells. When testing the intermediate PED with NIH 3T3 fibroblasts, no cell membrane damage 
was observed at any concentrations tested (Fig. 6b). MTT assay showed that 5 mg/ml of PED 
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caused a significant reduction in cell metabolism. Live/dead assay showed that 5 mg/ml of PED 
reduced the ratio of live to dead cells to 68 %. Overall, it was concluded that 1 mg/ml of PEAD 
or 2 mg/ml of PED did not cause cytotoxicity to NIH 3T3 cells. On the contrary, PEI showed high 
cytotoxicity; 0.01 mg/ml PEI was cytotoxic as indicated by all three assays (Fig. 6c). This is 
consistent with our prior results using primary baboon smooth muscle cells [95]. 
When testing PEAD with HAECs, LDH in the culture medium elevated and the metabolic 
activity dropped when the concentration of PEAD reached 10 mg/ml (Fig 6d). No increase in 
caspase-3 activity was observed at any concentration as NIH 3T3. Live/dead assay suggested 
that cell viability dropped when the concentration of PEAD reached 5 mg/ml. For PED, only MTT 
assay showed that cell metabolism was compromised when the concentration reached 5 mg/ml 
(Fig. 6e). Other assays revealed no difference with the control group. Overall, no cytotoxicity to 
HAECs was observed up to 5 mg/ml PEAD or 2 mg/ml PED. Compared to PEAD or PED, 0.01 
mg/ml of PEI showed significant cytotoxicity to HAECs as it did to NIH 3T3 cells (Fig. 6f).  
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Figure 6. Comparison of in vitro biocompatibility of PEAD, PED and PEI by NIH 3T3 (a-c) and 
HAECs (d-f). For NIH 3T3 cells, PEAD did not compromise cell membrane at 1 mg/ml, reduce 
cellular metabolism at 5 mg/ml, or activate caspase-3 for all concentrations tested, and also had 
no impact on the ratio of live to dead cells at 5 mg/ml (a). PED reduced cellular metabolism and 
reduced the ratio of live to dead cells to 68 % when the concentration reached 10 mg/ml (b). 
PEI, however, showed high cytotoxicity; 0.01 mg/ml PEI was cytotoxic as indicated by all three 
assays (c). For HAECs, PEAD elevated LDH in the culture medium and dropped metabolism at 
10 mg/ml, and also lowered cell viability at 5 mg/ml (d). PED compromised cellular metabolism 
when the concentration reached 5 mg/ml (e). 0.01 mg/ml of PEI showed significant cytotoxicity 
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to HAECs as it did to NIH 3T3 cells (f). Overall, the in vitro study demonstrated that PEAD and 
PED have much higher biocompatibility than PEI. *p  value < 0.05. 
 
According to the results of MTT assays reported previously using L929 mouse 
fibroblasts, many existing polycations had IC50 values lower than 0.5 mg/ml. These include poly-
L lysine (PLL), poly(diallyl-dimethyl-ammonium chloride), poly(vinyl pyridinium bromide) and 
diethylaminoethyldextran, or 0.1 mg/ml polyethylenimine (PEI) [94]. MTT assays showed that 
even at 10 mg/ml, PEAD only reduced the metabolic activity to 75 % and 65 % for NIH 3T3 and 
HAECs respectively. In addition, PEI and PLL have been demonstrated to induce apoptosis in 
multiple cell lines according to caspase-3 assays [87]. In contrast, caspase-3 activity showed no 
significant increase at any concentration tested for PEAD and PED. Previous accounts of 
different polycation toxicities were obtained using a variety of cell lines, but common observation 
was that synthetic polycations have low biocompatibility in genera [87,90]. PEAD was tested 
with both cell line and immortalized human cells. Combined, the in vitro assays indicated that 
PEAD showed no cytotoxicity to either NIH 3T3 cell line or primary HAECs, at 1 mg/ml. 
Structurally, the difference between PED and PEAD is that the latter carries arginine. The 
biocompatibility of PEAD and PED showed no difference at 2 mg/ml. At 5 to 10 mg/ml, the 
biocompatibility of PEAD appeared to be higher than PED. This is opposite of the inverse 
relationship between charge density and biocompatibility observed in other series of polycations 
and the mechanism awaits further investigation [90].  
Examination of in vivo biocompatibility by subcutaneous injection 
To complement the in vitro studies, the in vivo biocompatibility of PEAD was further 
investigated. 100 µl of PEAD solution (10 mg/ml) was injected subcutaneously in rats. 3, 7 and 
28 days post-injection were chosen to observe the progression of acute to long term effects of 
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PEAD injection. No discernable difference was observed between the tissue responses at the 
different time points. The micrographs show that hematoxylin and eosin (H & E) staining of the 
tissues harvested at day 3 displayed normal tissue architecture for the connective tissue and the 
muscle surrounding the injection site (Fig. 7) and major organs including lung, liver and kidney 
(Fig. 8). No appreciable inflammation or necrosis was observed. In addition, there were no 
associated atypical or transformed malignant cells. However, under identical conditions, PEI 
caused severe damage to the connective tissues and muscles surrounding the injection site. 
The connective tissues were widely infiltrated by neutrophils and plasmocytes, and showed 
extensive inflammation. The muscle fibers in the injection zone showed severe degeneration 
and necrosis accompanied by significant inflammatory infiltrates. 
 
Figure 7. Comparison of in vivo biocompatibility of PEAD and PEI by H&E staining. The tissues 
from the healthy animals were used as the controls, (a) connective tissues and (b) muscles. The 
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animals injected with PEAD exhibited no difference from healthy controls 3 day post-injection. 
No appreciable inflammation or necrosis was observed at the injection site, (c) and (d). PEI, 
however, showed serious cytotoxicity to the tissues. (e) The connective tissues were widely 
infiltrated by neutrophils and plasmocytes and exhibited extensive inflammation. (f) The muscle 
fibers were degenerated and suffered significant necrosis. Scale bar = 50 µm. The same was 
observed for tissues harvested at days 7 and 28. 
 
 
Figure 8. H & E staining of tissues harvested at day 3 post-injection. Both PEAD (a-c) and PEI 
(d-f) showed normal morphology. Liver: (a) and (d). Lung: (b) and (e). Kidney: (c) and (f). Scale 
bar = 50 µm. 
 
PEI is currently the most widely used polycation in gene delivery. Although the in vivo 
efficacy has been demonstrated, its high cytotoxicity is still an issue which compromises the 
clinical value. Tail-vein injection of 0.02 mg of PEI (25 kDa) in mice can cause necrosis and 
apoptosis in the lung, liver, spleen and kidney [94]. Similarly, according to our previous 
experiment, injecting 0.2 mg of PEI (10 kDa) intraperitoneally caused severe necrosis and 
apoptosis in the liver of mice at day 1 post injection [95]. Here, at least 1 mg of PEAD was 
shown to have no in vivo cytotoxicity when injected subcutaneously whereas the same amount 
 35 
of PEI caused serious damage to the tissue at the injection site. It is possible that a larger 
amount of PEAD could be injected without causing adverse reactions in vivo. 1 mg of PEAD 
was tested because this was expected to be the upper limit of our in vivo applications [102].  
Zeta potential measurement of [PEAD:polyanion] complexes 
Under physiological conditions, PEAD bears > 1 positive charge per repeating unit and 
should interact strongly with negatively charged macromolecules through Coulombic attraction. 
DNA (plasmid pEYFP-N1) and hyaluronic acid (HA) were chosen to represent two important 
classes of biological polyanions, nucleic acids and glycosaminoglycans. Upon addition of PEAD 
to DNA solution, the zeta potential changed from negative to neutral and then positive (Fig. 9). 
At a PEAD to DNA mass ratio of approximately 1.5, the complex became neutral, indicating that 
all negative charges on the DNA were neutralized by PEAD. Adding more PEAD after this 
isoelectric point was reached caused [PEAD:DNA] complexes to become positively charged, 
reaching a plateau at +23.9 mV which is similar to the potential of PEAD (+23.1mV). The same 
trend was observed during the addition of PEAD into hyaluronic acid. The isoelectric point for 
[PEAD:HA] complex was obtained at a polycation/polyanion mass ratio of approximately 4. The 
only difference was that the plateau potential of [PEAD:HA] complex was +11.1 mV, lower than 
that of [PEAD:DNA] complex. It was hypothesized that different plateau potentials are caused 
mainly by intrinsic properties such as viscosity and solubility of individual biological polyanions. 
Because zeta potential measurement does not account for these factors, [PEAD:DNA] and 
[PEAD:HA] complexes exhibited similar patterns but have different zeta potentials. The 
polyvalent nature of the interactions between PEAD and a polyanion suggests that the 
molecular weight of the polymeric components will affect their affinity. Therefore molecular 
weight of PEAD is expected to offer a convenient control of its interaction with polyanions in a 
similar fashion as poly(L-argininate glyceryl succinate) [96].  
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Figure 9. Monitoring Zeta potential during the titration of biological polyanions with PEAD 
suggested that PEAD had high affinity toward negatively charged macromolecules. (a) As more 
PEAD is added, the zeta potential of the [PEAD:DNA] complexes shifted from negative to 
neutral and then reached a plateau at approximately +23 mV. At the mass ratio close to 1.5, the 
complex is neutral. (b) The titration of [PEAD:HA] complex followed a similar pattern with a 
neutral complex formed  at the mass ratio of 4.   
Size measurement of [PEAD:polyanion] complexes 
Dynamic light scattering (DLS) was used to measure the hydrodynamic volume of 
macromolecules. DLS offers useful information on size of the [PEAD:polyanion] coacervate 
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even though DLS assumes the coacervate is spherical. In deionized water the average diameter 
of the [PEAD:DNA] complex at the isoelectric point was 245 nm with a standard deviation of 53 
nm. In saline, the diameter decreased to 150 nm with a standard deviation of 30 nm. Compared 
to [PEAD:DNA] complex, [PEAD:HA] complex had a much larger diameter in deionized water 
reaching 1,236 nm with a standard deviation of 124 nm, but in saline the diameter dropped 
significantly to 240 nm with a standard deviation of 20 nm. These results suggest that increasing 
ionic strength reduces the interaction between PEAD and polyanions. Differences between 
[PEAD:DNA] and [PEAD:HA] are likely caused by differences in size and electrostatic properties 
of individual polyanions. Furthermore, DLS and GPC data are consistent with a mostly linear 
structure of the polymer. Based on DLS measurement, the hydrodynamic diameter of PEAD is 
5.9 nm. The corresponding MW would be 214.2 kD, 257.0 kD, and 50.8 kD for globular, 
starburst, and linear polymers respectively. GPC analysis indicates that Mw of PEAD is 
approximately 30 kD. This matches the linear polymer (50.8 kD) best, therefore, PEAD is most 
likely linear. 
SEM micrographs of [PEAD:polyanion] complexes 
PEAD immediately forms a turbid solution with DNA or HA upon mixing. To reveal the 
morphology of the resultant ionic complexes, SEM was used to investigate the complexes at the 
isoelectric points. The micrograph shows that [PEAD:DNA] complex is mainly composed of 
fibers, beads, and sheets (Fig. 10a). The diameters of the fibers cover a wide range from sub-
micron to nanometers. [PEAD:HA] complex shares similar structures with [PEAD:DNA] 
complex, however, the fiber diameters are larger and there are more sheets and fewer beads 
(Fig. 10b). The factors that lead to the morphological differences between [PEAD:HA] and 
[PEAD:DNA] complexes are currently under investigation.  
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Figure 10. Scanning electron micrographs of the ionic complexes. (a) [PEAD:DNA] complex 
consists mainly of fibrous structures (arrow). The diameters of the fibers are typically less than 1 
µm. In addition, it also contains beads (arrowhead) and sheets (sh). 2,000X, scale bar = 10 µm. 
(b) [PEAD:HA] complex is mainly fibrous in nature and the fibers (arrow) have larger 
diameters.There are also sheet-like structures (sh) in the complex.  2,000X, scale bar = 20 µm. 
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3.1.4       Summary 
In the prior study, our laboratory proposed a design principle for biocompatible 
polycations: a biocompatible polycation should be biodegradable and made from endogenous 
cations [95]. Here, this study followed the same principle and applied a simple chemistry to 
synthesize a new arginine-based biodegradable polycation to further test this design. The 
reaction parameters can be adjusted easily to generate a series of polycations with different 
physical and chemical properties. PEAD assembles with biological polyanions and 
spontaneously forms three-dimensional structures in aqueous solution. PEAD offers higher 
biocompatibility than conventional polycations and may lead to advancements in many areas of 
biotechnology and medicine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 40 
3.2      APPLICATION OF [PEAD:HEPARIN] IN GROWTH FACTOR DELIVERY 
Growth factors are potent molecules that regulate cell functions including survival, self 
renewal, differentiation and proliferation. High-efficacy delivery of growth factors will be a 
powerful tool for regenerative medicine. Decades of intense research have significantly 
advanced the field of controlled delivery. There is, however, still a great unmet need for new 
methods that can improve overall efficacy of growth-factor delivery. Here, we report a new 
growth factor delivery vehicle formed by self assembly of heparin and a biocompatible 
polycation, poly(ethylene argininylaspartate diglyceride) (PEAD). Of the many heparin-binding 
growth factors, we chose FGF2 and NGF to demonstrate the potential of the [PEAD:heparin] 
delivery vehicle. The delivery vehicle incorporates both growth factors with high efficiency, 
controls their release, maintains the bioactivity of FGF2 and increases the bioactivity of NGF 
relative to bolus delivery. [PEAD:heparin] appears to be a promising delivery matrix for many 
heparin-binding growth factors and may lead to efficient growth factor delivery for a variety of 
diseases and disabilities. 
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3.2.1      Introduction 
Extracellular growth factors are usually associated with extracellular matrix (ECM) and 
rarely exist in free forms [103,104,105]. This allows for growth factors to be stored in the ECM 
which enables a rapid response to extracellular stimuli. This is highly beneficial because the 
activation of a growth factor expressing gene can take hours [106]. Growth factor binding also 
changes the conformation of the growth factors and modulates their interactions with receptors 
and their bioactivities [107,108,109]. Furthermore, the association can protect the growth 
factors from proteolytic degradation [110]. Heparan sulfate, a major component of the ECM, is a 
highly-sulfated glycosaminoglycan with high affinity to a large variety of growth factors 
[111,112]. Heparin has a similar structure to heparan, binds many growth factors, and is more 
readily available and more widely used in the research and application of growth factors [113]. 
We therefore decided to exploit the affinity between heparin and growth factors to achieve high-
efficiency delivery of heparin-binding growth factors. 
In order to maintain the native properties and function of heparin, we chose to use intact 
heparin without covalently linking heparin to the delivery matrix. A biocompatible polycation was 
chosen to ionically bind heparin to form the delivery vehicle. PEAD was a biodegradable 
polycation with high biocompatibility. Because of the high charge density, PEAD bound strongly 
to heparin and consequently incorporates growth factors with high efficiency. [PEAD:heparin] 
can control the release of the growth factors for over 30 days in a nearly linear fashion. More 
importantly, [PEAD:heparin] complex maintained the bioactivity of fibroblast growth factor-2 
(FGF2) and increased the bioactivity of nerve growth factor (NGF) when compared with bolus 
delivery. This new delivery vehicle was expected to be applicable to any heparin-binding growth 
factor and represent an innovative method of delivering single or multiple growth factors. 
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3.2.2      Experimental section 
Synthesis of PEAD 
The detailed synthetic procedures of PEAD are described in the supporting material. 
Briefly, PEAD was synthesized in two steps. (i) Ethylene glycol diglycidyl ether (EGDE) and t-
BOC protected aspartic acid were polymerized through a polycondensation reaction in 1,4-
dioxane under the catalysis of tetra-n-butylammonium bromide (TBAB). The t-BOC protective 
group was removed by 1:4 trifluoroacetic acid (TFA):dichloromethane (DCM) to generate the 
intermediate, poly(ethylene aspartate glyceride) (PED). (ii) Conjugation of t-BOC arginine to 
PED was performed by a dicyclohexylcarbodiimide (DCC)/N-hydroxysuccinimide (NHS)/4-
dimethylaminopyridine (DMAP) coupling reaction in dimethylforamide (DMF) followed by the 
second deprotection of t-BOC with TFA to yield PEAD. The chemical structure was 
characterized using a Mercury 400 NMR (Varian, Palo Alto, CA) and a Nicolet IR-100 
spectrometer (Thermo Fisher Scientific, Waltham, IL).  
Gel permeation chromatography (GPC) analysis 
The molecular weights of PEAD and heparin (Alfa Aesar, Ward Hill, MA) were measured 
with a PL-GPC 50 Plus- RI equipped with a PD 2020 light scattering detector (Varian, MA). For 
PEAD, two MesoPore 300x7.5 mm columns and 0.1% of LiBr in DMF were used as the 
stationary phase and mobile phase respectively. For heparin, the PL aquagel OH-40 and PL 
aquagel OH-30 columns were used as the stationary phase and the buffer solution containing 
0.2 M NaNO3 and 0.01 M NaH2PO4, pH 7 was used as the mobile phase. 
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Zeta potential measurement 
PEAD and heparin solutions were prepared in deionized water at a concentration of 1 
mg/ml. 100 μl of heparin solution was titrated with PEAD solution. 750 μl of water was added to 
dilute the complex before the measurements were taken. Zeta potentials were measured by a 
Zetasizer Nano Z (Malvern, Westborough, MA). The results were reported as mean with ± 
deviation for 30 measurements. The same instrument was used to measure and compare the 
hydrodynamic diameter of [heparin:FGF2] and [PEAD:heparin:FGF2] by dynamic light 
scattering.  
Dimethylmethylene blue assay 
Dimethylmethylene blue (DMB) was used for quantification of sulfated 
glycosaminoglycans according to published protocols [114,115]. Briefly, 20 μl of heparin 
solution (1 mg/ml) was mixed with different volumes of PEAD solution (1 mg/ml). Deionized 
water was added to the complex solution to reach a final volume of 220 μl. After a 5 min 
centrifugation at 12,100 g, 50 μl of supernatant was added to DMB working solution containing 
10.7 μg of 1,9-dimethylmethylene blue chloride (Polysciences, Warrington, PA) in 55 mM formic 
acid. The absorbance at 520 nm was determined by a SynergyMX plate reader (Biotek, 
Winooski, VT). A series of heparin solutions of known concentrations were used as standards to 
calculate the concentration of heparin in the supernatant. 
The amount of PEAD in the supernatant was quantified by an anionic dye, orange II 
(Acros Organics, Geel, Belgium) [116]. Briefly, 50 μl supernatant was added to 20 μl orange II 
solution (1mM) and gently agitated for 10 min. After centrifugation at 12,100 g for 5 min, 50 μl 
was used for absorption measurement at 484 nm. A series of PEAD solutions of known 
concentrations were used as standards to calculate the concentration of PEAD in the 
supernatant.  
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Scanning electron microscopy (SEM) 
The SEM samples were prepared by mixing PEAD with heparin (mass ratio of PEAD to 
heparin: 5) to form the complex. The complex was dropped on an aluminum stub, lyophilized, 
sputtered with gold and viewed with a Leo 1530 SEM (10 kV, 3 nm spot size) (Carl Zeiss SMT, 
Peabody, MA). 
Growth factor loading efficiency 
The loading efficiency of FGF2 was determined by an indirect enzyme-linked 
immunosorbent assay (ELISA). Briefly, 100 ng of bolus FGF2 or [PEAD:heparin:FGF2] was 
added to a 96-well plate and left overnight to allow protein adsorption. After blocking by bovine 
serum albumin (BSA), a rabbit anti-FGF2 polyclonal antibody (PeproTech, Rocky Hill, NJ) was 
used for recognition followed by a secondary antibody, goat anti-rabbit IgG HRP (Sigma-Aldrich, 
St. Louis, MO) and then a chromagen substrate, 3,3´,5,5´-tetramethylbenzidine (TMB) 
(Promega, Madison, WI). The absorbance at 450 nm was recorded by a SynergyMX plate 
reader (Biotek, Winooski, VT). The loading efficiency of NGF was determined by a sandwich 
ELISA using a commercial kit, NGF Emax® ImmunoAssay Systems (Promega, Madison, WI). 
Briefly, an anti-NGF polyclonal antibody was coated on a 96-well plate. After blocking by BSA, 
[PEAD:heparin:FGF2] was added for incubation, followed by the recognition of an anti-NGF 
monoclonal antibody and an anti-rat IgG HRP.  
Growth factor release profile 
FGF2 and NGF were labeled with 125I. Briefly, 100 µl of FGF2 (0.1 mg/ml) or NGF (0.2 
mg/ml) was transferred to a Pierce Iodination Tube (Thermo Fisher Scientific, Waltham, IL). 15-
20 µl of carrier-free Na125I (PerkinElmer, Waltham, MA) was added to the tube, and the reaction 
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proceeded for 2 min. The crude reaction mixture was purified by size exclusion chromatography 
and the product was stored at -20 °C.  
The controlled delivery matrix was formed by combining 100 ng of growth factor with 0.1 
ng of 125I labeled growth factor to 10 μl of heparin (10 mg/ml) followed by the addition of 50 μl of 
PEAD solution (10 mg/ml). The solution was gently mixed and centrifuged at 12,100 g for 5 min. 
After removal of the supernatant, 500 μl of 0.9% saline was added to cover the pellet. At 
predetermined time points (day 1, 4, 7, 14, 19, 28, 33 and 42), the supernatant was collected 
and replaced with fresh saline. The radioactivity of the collected supernatant was measured by 
a Packard Cobra II Gamma Counter (PerkinElmer, Waltham, MA) to determine the amount of 
the released growth factor. 
FGF2 bioactivity 
FGF2 bioactivity was determined by its stimulatory effects on the proliferation of human 
aortic endothelial cells (HAECs). Briefly, HAECs were cultured on a 24-well plate with MCDB 
131 medium (Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (FBS), 1% 
L-glutamine and 50 µg/ml ascorbic acid. A cell culture insert (BD Biosciences, San Jose, CA) 
with 1.0 μm pores was placed in each well. 100 ng of FGF2 (PeproTech, Rocky Hill, NJ) alone 
or [PEAD:heparin:FGF2] was added on the insert. Two control groups were applied in the study: 
(1) basal medium: medium without supplemental growth factors, and  (2) Endothelial cell (EC) 
culture supplement: medium containing 1 ng/ml epithelial growth factor (EGF), 2 ng/ml FGF2, 2 
ng/ml insulin-like growth factor-1 (IGF1), 1 ng/ml vascular endothelial growth factor (VEGF) and 
1 µg/ml hydrocortisone as provided by the supplier of HAECs (Sigma-Aldrich, St. Louis, MO). 
After culturing for 4 days, the proliferation of HAEC was determined by a CyQuant Cell 
Proliferation Assay (Invitrogen, Carlsbad, CA). All results were normalized to the basal medium 
group. 
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NGF bioactivity 
NGF bioactivity was determined by its ability to stimulate neuronal differentiation of PC-
12 cells. [117] PC-12 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
(Mediatech, Manassas, VA) supplemented with 1.0% horse serum (HS) and 0.5% FBS. Delivery 
vehicle [PEAD:heparin], bolus NGF (Promega, Madison, WI), NGF stabilized by heparin 
[heparin:NGF] or delivery matrix [PEAD:heparin:NGF] was added to the cell culture insert. The 
controls were basal medium without NGF and bolus NGF. All NGF groups contained 10 ng of 
NGF. On day 4 and day 7, five fields were randomly selected and the phase contrast images 
were acquired using an inverted microscope Eclipse Ti (Nikon, Melville, NY) equipped with a 
RETIGA-SRV digital camera (QImaging, BC, Canada). The neurite lengths were measured 
using NIH ImageJ software version 1.42. The average length of the ten longest neurites was 
reported with standard deviation. 
Statistical analysis 
ANOVA followed by post-hoc Bonferroni test was used to analyze the data for the 
bioactivity of FGF2 and NGF. Data is presented as mean ± standard deviations. * p value < 
0.05; ** p value < 0.01.  
 
3.2.3      Results 
Zeta potential measurement of [PEAD:heparin] complex 
PEAD was synthesized by polycondensation of aspartic acid and ethylene glycol 
diglycidyl ether (EGDE), followed by the conjugation of arginine which provided positive charges 
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to the polymer. PEAD has two cationic groups (amine and guanidine) per repeating unit, thus it 
interacts strongly with heparin, the most negatively charged natural polymer, through Coulombic 
forces. We observed that heparin solution became turbid upon addition of PEAD as the negative 
charge of heparin was neutralized (Fig. 11). The highest turbidity was reached with a PEAD to 
heparin mass ratio of 5, indicating that the [PEAD:heparin] complex is likely neutral at this ratio. 
We used zeta potential titration to analyze the charge of the complex. The zeta potential of the 
complexes shifted from -45 mV at a mass ratio of 1, to neutral at the mass ratio close to 5 and 
to +23.2 mV at a ratio of 10 (Fig. 12). The zeta potential at the plateau (+23.2 mV) was similar to 
that of pure PEAD (+23.1 mV), suggesting that the complex was completely saturated with 
PEAD. The titration revealed that at a PEAD to heparin mass ratio close to 5 (molar ratio of 3.4), 
PEAD completely neutralized the negative charges of heparin. Because the binding between 
PEAD and heparin is based on ionic interaction, we also observed that ionic strength of the 
delivery matrix solution affected the binding between PEAD and heparin. When PEAD and 
heparin were mixed in 10-fold saline (9 % NaCl(aq)), no coacervate was observed by the naked 
eye. We can therefore conclude that ionic interaction is the major force between PEAD and 
heparin.     
 
Figure 11. Macroscopic observation of [PEAD:heparin] complex. Both heparin and PEAD have 
excellent solubility in aqueous solution. Addition of PEAD into heparin solution neutralized the 
negative charge of heparin and formed insoluble [PEAD:heparin] coacervate. The complex 
settled down to the bottom after 24 h. 
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Figure 12. Binding of PEAD to heparin monitored by zeta potential titration. The [PEAD:heparin] 
complex reached isoelectric point at a PEAD:heparin mass ratio close to 5 (molar ratio 3.4). 
Over-titration with PEAD gave the complex excessive positive charge that leveled off at +23.2 
mV at a mass ratio of 10. Data represent the average and the standard deviation of 30 
measurements. 
DMB binding assay of [PEAD:heparin] complex 
The ionic interaction of PEAD and heparin decreased their solubility in water and the 
polymers formed a coacervate. We calculated the binding affinity between PEAD and heparin 
by measuring the amount of each left in the supernatant. Heparin quantification was performed 
using a heparin binding dye, dimethylmethylene blue (DMB). The results suggest that the 
amount of heparin in the supernatant decreased gradually with the addition of PEAD (Fig. 13). 
Maximum binding of heparin, 98.7%, was reached with a PEAD to heparin mass ratio of 5. 
Similarly, using an anionic dye, orange II, we quantified the amount of PEAD in the supernatant 
at a mass ratio of 5 to be 5.0%.  
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Figure 13. Binding of PEAD to heparin as monitored by DMB assay. The amount of heparin in 
the solution phase decreased as PEAD was added until maximal binding at a PEAD:heparin 
mass ratio of 5 where only 1.33% of heparin was left in the supernatant. At ratios greater than 5, 
excessive positive charge on the complex likely caused a slight reduction in coacervation. Data 
represent an average of four independent assays.   
According to the GPC analysis, the weight-average molecular weight (Mw) of PEAD is 
30,330 Da (PDI = 2.28) and that of heparin is 20,700 Da (PDI = 1.20). These values and the 
amount of PEAD, heparin, and [PEAD:heparin] complex was used to calculate the stoichiometry 
of [PEAD:heparin]. The result revealed that approximately 3.3 PEAD molecules bind to 1 
heparin molecule. The dissociation constant (Kd) of PEAD and heparin was 1.55×10-10 as 
calculated according to the following equations: 
      [PEAD3.3heparin]  3.3 [PEAD] + [heparin]                                   (1)  
            Kd = [PEAD]3.3[heparin][PEAD3.3heparin]                                                                      (2) 
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SEM of [PEAD:heparin] complex 
We examined the morphology of [PEAD:heparin] complex using scanning electron 
microscopy (SEM). The micrographs revealed that a neutral [PEAD:heparin] complex was 
largely composed of ribbon-like structures with globular domains of various sizes dispersed 
throughout the matrix (Fig. 14a). The diameters of the ribbons ranged from nanometers to 
micrometers. The globules might originate from heparin as the micrograph of heparin showed 
mainly beads with diameters below 1µm (Fig. 14c). On the other hand, the ribbon-like 
morphology was likely generated by PEAD (Fig. 14d). Dynamic light scattering measurement 
revealed that [heparin:FGF2] has a hydrodynamic diameter of 181.9 nm with a polydispersity 
index of 0.478. Addition of PEAD significantly increased the diameter to 540.8 nm with a 
polydispersity index of 0.489. 
 
         
          
Figure 14. Scanning electron micrographs of the [PEAD:heparin] complex at (a) Low 
magnification (2,000 X) and (b) High magnification (10,000 X). The complex consists of ribbon-
(c)                                                         (d)  
(a)                                                         (b)  
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like structure and beads with diameters ranging from nanometers to a few microns. (c) Heparin 
contains beads with diameters in the sub-micron range (20,000 X). (d) PEAD contains mostly 
ribbon-like structures (10,000 X). 
Growth factor loading efficiency of [PEAD:heparin] complex 
Loading efficiency is another critical parameter of effective growth factor delivery. We 
examined growth factor loading efficiency of [PEAD:heparin] by ELISA. Less than 0.01% of 
FGF2 was detected in the supernatant by an anti-FGF2 polyclonal antibody. Similarly, less than 
0.02% of NGF was detected in the supernatant. This data indicates that [PEAD:heparin] can 
incorporate more than 99% of FGF2 and NGF. 
Release of growth factors bound to [PEAD:heparin]  
To investigate the release rate of the incorporated growth factors from the delivery 
vehicle we determined the release profiles of [PEAD:heparin]-bound growth factors by 
measuring the radioactivity of the supernatant. FGF2 release showed an initial burst of 
approximately 10% after one day (Fig. 15a). Thereafter, the release was nearly linear and 
sustained through the end of the 42-day experiment. At day 42, [PEAD:heparin:FGF2] complex 
still contained about 60% of FGF2. As expected, NGF showed a faster release profile due to its 
lower affinity for heparin. The initial burst released almost 20%, followed by a sustained release 
for 20 days (Fig. 15b). At day 20, [PEAD:heparin:NGF] complex still contained approximately 
30% of NGF and the coacervate was radioactive. The residual NGF could be bound too tightly 
to [PEAD:heparin] and unable to be released by simple diffusion, however the remaining growth 
factor may be released if exposed to enzymes such as heparinase or esterase. Overall, the 
release profile of each growth factor reflected its respective heparin-binding affinity. The initial 
burst is likely caused by loosely adsorbed growth factors and growth factors physically trapped 
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in the delivery vehicle. This could be avoided, in part, by washing the delivery matrix 
immediately after its formation. 
 
 
Figure 15. Release profiles of growth factors bound to [PEAD:heparin] indicating that 
[PEAD:heparin] complex can control the release of the incorporated growth factors. (a) FGF-2: 
The initial burst (~10%) was limited to day 1 only. Thereafter the release was nearly linear and 
lasted for at least 42 days. (b) NGF: The initial burst was approximately 20% and the steady 
release was sustained for 20 days, at which point it reached a plateau. The remaining NGF may 
be too tightly bound to [PEAD:heparin], making it difficult to be released by simple diffusion 
under the test conditions. The quicker release of NGF compared to FGF-2 matches its weaker 
affinity for heparin. 
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Bioactivity of FGF2 delivered by [PEAD:heparin] 
The most important feature of a growth factor delivery vehicle is its ability to maintain the 
bioactivity of its bound growth factors. We tested the ability of [PEAD:heparin] to maintain the 
bioactivity of FGF2 and NGF, chosen because of their high and low heparin affinities; the Kd 
values for FGF2 and NGF are 2.0 and 600 nM, respectively [118]. To evaluate FGF2 bioactivity, 
we compared the proliferation of human aortic endothelial cells (HAECs) cultured in basal 
medium, medium supplemented with manufacturer-supplied EC culture supplement, medium 
with bolus FGF2, and medium with [PEAD:heparin:FGF2]. After 4 days of culture, bolus FGF2 
and [PEAD:heparin:FGF2] promoted higher proliferation than the basal medium and EC culture 
supplement groups (Fig. 16). Cell proliferation in the presence of [PEAD:heparin:FGF2] was 
2.69 times higher than that of the basal medium and 1.26 times higher than that of EC culture 
supplement. There was no statistical difference between cell proliferation for bolus FGF2 and 
[PEAD:heparin:FGF2], suggesting that FGF2 bioactivity was well preserved in the delivery 
matrix. 
 
 
Figure 16. HAEC proliferation under different culture conditions: 1. basal medium, 2. EC culture 
supplement, 3. bolus FGF-2, and 4. [PEAD:heparin:FGF-2]. Data represent the average of 3 
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independent experiments and standard deviation. ** indicates p value < 0.01 when comparing 
bolus FGF-2 or [PEAD:heparin:FGF-2] to the controls (groups 1 and 2). For both bolus FGF-2 
and [PEAD:heparin:FGF-2], HAECs exhibited significantly higher proliferation after 4 days of 
culture. There was no statistical difference observed between bolus and [PEAD:heparin:FGF-2] 
suggesting that the delivery vehicle maintains FGF-2 bioactivity well. 
Bioactivity of NGF delivered by [PEAD:heparin] 
NGF is known to have a lower heparin affinity than FGF2 [17]. To examine the bioactivity 
of NGF we chose to use the common and well-established cell line, PC-12. Upon stimulation by 
NGF, PC-12 cells would start to differentiate into neuron-like cells and begin to extend neurites. 
Neurite length is widely used as an index to determine NGF bioactivity [18]. This study included 
five groups: control (neural basal medium without NGF), delivery vehicle [PEAD:heparin], bolus 
NGF, [heparin:NGF], and [PEAD:heparin: NGF]. After 4 days of culture, all three NGF-
containing groups had significantly longer neurites than the control and the delivery vehicle 
groups which displayed reduced or no neurite extension (Fig. 17a). There was no statistical 
difference between the control group and the delivery vehicle group. This suggests that the 
delivery vehicle had no bioactivity. The [heparin:NGF] group showed significantly longer neurite 
extension than the bolus group. On day 4 there was no statistical difference between 
[PEAD:heparin:NGF] and the bolus or [heparin:NGF] group. However, after 7 days, there was a 
statistically significant difference between each group (Fig. 17a, b). For bolus NGF and 
[heparin:NGF], the neurite lengths decreased between day 4 and day 7, suggesting reduced 
NGF activity. [PEAD:heparin:NGF], on the contrary, continued to promote differentiation and 
stimulate neurite extension, increasing average neurite length 2.3 fold from day 4 to day 7 (48 
µm to 108 µm). On day 7, the average neurite length of the [PEAD:heparin:NGF] group was 2.8 
times and 3.6 times longer than that of the [heparin:NGF] and bolus group, respectively, 
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indicating that the [PEAD:heparin] delivery vehicle most effectively maintains and potentiates 
NGF bioactivity. 
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Figure 17. PC-12 cell differentiation stimulated by NGF: 1. control, 2. [PEAD:heparin], 3. bolus 
NGF, 4. [heparin:NGF] and 5. [PEAD:heparin:NGF]. (a) Three independent experiments were 
(a) 
(b) 
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performed. Data represent the average length of the ten longest neurites with standard 
deviation. * p value < 0.05; ** p value < 0.01. At 4 days, [heparin:NGF] and [PEAD:heparin:NGF] 
showed similar bioactivity and were more effective than bolus NGF, control, and 
[PEAD:heparin]. However, [PEAD:heparin:NGF] was the only group to exhibit continued 
extension of neurites beyond day 4. The average neurite length reached 108 µm which was 
significantly longer than that of either the bolus or [heparin:NGF] group. (b) Phase contrast 
images of the PC-12 cells at day 7. Only PC-12 cells cultured in the presence of 
[PEAD:heparin:NGF] fully spread out and generated an extensive network of neurites. Bolus 
NGF and [heparin:NGF] groups not only exhibited atrophy in neurites, but also cell soma. 
 
 
 
 
3.2.4      Discussion 
Growth factor delivery using natural or synthetic materials has great therapeutic potential 
in biomedicine and biotechnology. In regenerative medicine, controlled release of growth factors 
has been applied in many applications including angiogenesis [119,120], nerve repair [121,122] 
and bone and cartilage regeneration [123,124]. Important parameters in growth factor delivery 
include bioactivity, loading efficiency and controlled release rate. Native growth factors are 
usually bound to, protected and controlled by the ECM, often through heparan sulfate. Heparin 
shares a similar structure with heparan sulfate and is widely used in growth factor delivery. 
However, heparin stabilized growth factors are water soluble and not amenable to controlled 
release by heparin alone. To solve this problem and improve the efficacy of growth factor 
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therapy, much research effort has been devoted to mimicking the structure of heparin or 
immobilizing heparin in order to regulate the distribution of heparin-binding growth factors. For 
example, Wenk, E. et al. decorated silk fibroin with sulfonic acid moieties by a diazonium 
reaction to mimic natural heparin [125]. Tae, G. et al. functionalized heparin with 
hydroxybenzotriazole and crosslinked with polyethylene glycol (PEG) to form a hydrogel [126]. 
Nilasaroya, A. et al. modified heparin with glycidyl methacrylate then photopolymerized with 
PEG dimethacrylate [127]. Seal, B. L. et al. attached heparin-binding sequences (12 to 17-mer) 
to PEG arms to conjugate heparin [128]. Similarly, Rajangam, K. et al. integrated heparin-
binding sequences (15-mer) to immobilize heparin on the surface of self-assembled nanofibers 
[129]. Johnson, P.J. et al. applied a bi-domain chimera containing the heparin-binding sequence 
(12-mer) to immobilize heparin in the fibrin gel [130]. The advantage of the latter three methods 
is that heparin was not covalently modified and was able to interact with growth factors directly, 
thus fully preserving the natural bioactivity of heparin. In the research reported here, a 
polycation interacts directly with native heparin without modification. The advantages of this 
approach are that PEAD is easily synthesized and provides a cost-effective platform for intact-
heparin-based growth factor delivery. Furthermore, the affinity between PEAD and heparin is 
extremely high, and thus it is expected to incorporate high amount of heparin-binding growth 
factors and control their release well. This is complemented with the ability to retain and 
promote growth factor bioactivity as demonstrated in the in vitro assays. 
PEAD interacts strongly with heparin and neutralizes its inherent negative charges. This 
charge neutralization decreases the solubility of individual molecules and induces the formation 
of a coacervate immediately upon mixing. The coacervate confines the growth factor; 
furthermore heparin binds the growth factors. These two factors together control the release of 
the growth factors. We believe that the release kinetics of growth factors bound to 
[PEAD:heparin] can be tailored by: (i) The amount of heparin used in complex formation. More 
heparin is expected to slow the release of the growth factor. (ii) The properties of PEAD such as 
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molecular weight and charge density can alter its interaction with heparin which in turn, modifies 
the release kinetic of the growth factors. These properties can be easily adjusted during polymer 
synthesis. 
Regarding the bioactivity of growth factors bound to [PEAD:heparin] complex , the 
results demonstrated that the bioactivity of the growth factors studied was well maintained or 
even enhanced compared to bolus and heparin-protected growth factors. [PEAD:heparin:FGF2] 
promoted HAEC proliferation to the same level as bolus FGF2 up to day 4 (Fig. 16). Since the 
release profile indicates that only 13% of the loaded FGF2 was released during the first 4 days 
(Fig. 17a), it can be deduced that [PEAD:heparin:FGF2] is able to prolong the activity of FGF2 
compared to the bolus form. The neurite outgrowth study using PC-12 cells further supports this 
conclusion, showing a substantial increase in average neurite length after 7 days for cells 
cultured in [PEAD:heparin:NGF] compared to all other groups. The average neurite length for 
the bolus and [heparin:NGF] groups at day 7 were shorter than those of day 4, indicating that 
the bioactivity of bolus NGF and [heparin:NGF] could not be sustained over a long period of 
time. 
There are a few possible non-exclusive mechanisms to explain the enhanced bioactivity 
of NGF by [PEAD:heparin]: (i) [PEAD:heparin] complex incorporates the growth factors in a 
coacervate and shields them from proteolytic degradation, thereby extending the half life of the 
growth factor. (ii) The binding of the growth factors to [PEAD:heparin] complex concentrates the 
growth factors and consequently more growth factors are simultaneously presented to the target 
cells. (iii) Compared to bolus growth factor or heparin-bound growth factor alone, 
[PEAD:heparin]-bound growth factor allows for release in a temporally and spatially controlled 
manner. 
[PEAD:heparin] complex also exhibited the ability to release growth factors in a steady 
fashion (Fig. 15). Furthermore, PEAD has several specific features that enhance its usefulness 
in growth factor delivery: (i) Because of its high biocompatibility and the high affinity between 
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heparin and many growth factors, it is possible to deliver greater amounts of heparin-binding 
growth factors if clinically necessary. (ii) The charge density of PEAD can be adjusted easily by 
changing the molar ratio of arginine used in conjugation. It is highly possible that the charge 
density would affect the interaction between PEAD and heparin and therefore alter the release 
kinetics of growth factors. This will be investigated more thoroughly in future experiments. (iii) 
The assembly of PEAD, heparin and growth factors is performed in an aqueous solution, thus 
the bioactivity of the growth factor is better maintained than approaches that require organic 
solvents. (iv) [PEAD:heparin:growth factors] are injectable suspensions allowing for minimally 
invasive administration.  
 
 
 
 
3.2.5      Summary 
This study investigates a new growth factor delivery vehicle formed by self assembly of a 
polycation and heparin. The association of growth factors, native heparin, and PEAD in an 
aqueous buffer is expected to maximize the interactions between heparin and the growth 
factors. We have demonstrated that [PEAD:heparin] complex can load heparin-binding growth 
factors with high efficiency, control their release in a steady manner and maintain or enhance 
their bioactivity. Furthermore, the polycation is easily synthesized and cost effective compared 
to existing delivery strategies which utilize the entire heparin-binding domain. The results 
suggest that this delivery vehicle warrants extensive further investigations.  
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4.0       THERAPEUTIC ANGIOGENESIS VIA FGF2 COACERVATE 
Therapeutic angiogenesis via growth factor delivery has potential in treatment of many 
human diseases, especially cardiovascular-related. However, due to the insufficient bioactivity 
of the delivered factors, the nascent blood vessels usually do not have enough stability and 
regress over time. Here, the ability of [PEAD:heparin] coacervates to deliver an angiogenic 
factor was examined in two in vivo models. 
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4.1      IN VIVO ANGIOGENIC ACTIVITY OF FGF2 COACERVATE 
FGF2, a potent angiogenic factor, has the ability to induce the proliferation of endothelial 
cells, similar to vascular endothelial growth factor. In addition, FGF2 has ability to stimulate 
mural cells to associate and stabilize the endothelial tubes. We anticipate that if the bioactivity of 
FGF2 is well preserved, mature blood vessels will be generated even at low dosage of applied 
FGF2. In a rodent model, FGF2 containing coacervate was subcutaneously injected and long 
term angiogenesis was monitored. For comparison, the hemoglobin concentration at the 
injection site was measured. The expression of associated markers was evaluated to determine 
the maturity of neovasculature. It was expected that the [PEAD:heparin] coacervate can 
effectively enhance the bioactivity of FGF2. 
 
 
 
 
4.1.1      Introduction 
Angiogenesis is a physiological process involving the formation of nascent vasculature 
from existing blood vessels. The complex interactions between endothelial cells and mural cells 
including vascular smooth muscle cells and pericytes are highly coordinated by various signals 
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[131,132]. Therapeutic angiogenesis is promising in treating many human diseases especially 
coronary and peripheral ischemia [133,134]. Among various approaches to therapeutic 
angiogenesis, delivery of growth factors is the most simple and direct because it doesn’t need 
viral vectors in gene therapy or cells in cell therapy. Direct injection of free growth factors failed 
to demonstrate efficacy in clinical trials [135]. Therefore, appropriate controlled delivery strategy 
for growth factor is highly desirable and extensively studied. However, loading capacity and long 
term efficacy still present significant challenges to growth factor delivery.  
In the human body, most secretory growth factors are associated with extracellular 
matrix usually through interactions with glycosaminoglycans. Glycosaminoglycans are 
negatively charged linear polysaccharides that can have different composition, function and 
distribution in the body [136]. Together with other extracellular matrix molecules, 
glycosaminoglycans provide a substratum for cell attachment [137]. Furthermore, their 
interaction with growth factors is critical in many biological processes such as development 
[138,139] and cancer progression [140,141]. Heparin and heparan sulfate are well studied 
glycosaminoglycans for their high affinity to a variety of growth factors including heparin-binding 
epidermal growth factor (HB-EGF), fibroblast growth factor (FGF) and vascular endothelial 
growth factor (VEGF) families [142]. Heparin can modulate the conformation of the growth 
factors [143,144], protect them from proteolytic cleavage [145] and potentiate their bioactivity 
[146]. Incorporation of heparin in a delivery vehicle is therefore a promising approach to 
preserve the bioactivity of the delivered growth factors [147,148]. 
The FGF family is well known for its high affinity to heparin which modulates the 
interaction between FGFs and their receptors. As revealed by the crystal structure, the heavily 
anionic heparin brings the cationic sequences on FGF and its receptor closely together and 
stabilizes the ternary complex largely through polyvalent ionic interactions [149]. In order to 
mimic the interactions between these three components, a synthetic polycation substituted the 
heparin-binding sequence of the FGF receptor and form a ternary complex containing the 
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polycation, heparin and FGF. We designed a polycation, poly(ethylene argininylaspartate 
diglyceride) (PEAD) with excellent biocompatibility to conjugate heparin and a potent angiogenic 
factor, FGF2 [150,151].  The complex of heparin and FGF2 is soluble in water and not 
amenable to controlled local delivery. The addition of PEAD neutralized the excess negative 
charge of heparin and immediately induced the formation of [PEAD:heparin:FGF2] coacervates. 
This anchors FGF2 and enabled its controlled release. Charge interaction between PEAD and 
heparin was utilized instead of covalent modification of heparin in an effort to minimize the 
perturbation of the functions of heparin. As a result, FGF2 released from the coacervate induced 
much more potent angiogenic responses than free FGF2 in mice: mural cell participation 
significantly increases and the neo-vasculature is mature and persists to at least 4 weeks.  
 
 
 
 
4.1.2     Experimental section 
Synthesis of PEAD 
            PEAD was synthesized in two steps: (1) Ethylene glycol diglycidyl ether and t-BOC 
protected aspartic acid were polymerized through a polycondensation reaction in 1,4-dioxane 
under the catalysis of tetra-n-butylammonium bromide. The t-BOC protective group was 
removed by stirring in 1:4 trifluoroacetic acid (TFA):dichloromethane to yield the intermediate, 
poly(ethylene aspartate glyceride). (2) Conjugation of t-BOC arginine to poly(ethylene aspartate 
glyceride) was performed by a standard dicyclohexylcarbodiimide/N-hydroxysuccinimide 
coupling reaction in dimethylforamide followed by the removal of t-BOC with TFA to obtain 
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PEAD. The chemical structure was characterized using an UltraShield Plus 600 NMR (Bruker 
BioSpin) and a Nicolet iS10 spectrometer (Thermo Fisher Scientific). 
Delivery vehicle preparation and scanning electron microscopy 
For preparation of the delivery vehicle, PEAD dissolved in deionized water was mixed 
with heparin solution under constant stirring and the solution immediately became cloudy as the 
delivery vehicle (empty coacervate) formed. The complex was dropped on an aluminum stub, 
lyophilized, sputtered with gold, and the morphology was examined by a Jeol 6335 field 
emission gun SEM (Jeol). 
Analysis of FGF2 loading efficiency by Western blotting 
            PEAD and heparin were each dissolved in normal saline (0.9 % NaCl(aq)) to obtain 10 
mg/ml solutions. For preparation of the coacervate, 100, 500 ng or 1,000 ng of FGF2 
(PeproTech) was first mixed with 10 μl of the heparin solution and then 50 μl of the PEAD 
solution. The coacervate was equilibrated at room temperature for 15 min followed by 
centrifugation at 12,100g for 10 min. The supernatant and the pellet were mixed with the 
common sample buffer and denatured at 95°C for 5 min. 15 % of sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) was utilized for separation followed by protein 
blotting on a polyvinylidene fluoride (PVDF) membrane. A rabbit anti-human FGF2 polyclonal 
antibody (PeproTech) was applied for recognition followed by a secondary horse peroxidase 
conjugated anti-rabbit IgG antibody (Sigma). The intensity of the individual band was 
determined by NIH ImageJ software and compared with that of the FGF2 loading solution. 
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Protection from proteolysis by the coacervate 
Trypsin digestion of FGF2 was evaluated as previously described [152]. Briefly, FGF2 
(100 ng) alone, heparin-bound FGF2 (100 μg of heparin and 100 ng of FGF2) or the coacervate 
(500 μg of PEAD, 100 μg of heparin and 100 ng of FGF2) was incubated with 2 μg of trypsin at 
37°C for 30 min or 2 h. The digested solution was mixed with the sample buffer and denatured 
at 95°C for 5 min. Following the identical method, western blotting was utilized to examine the 
amount of intact FGF2. 
Bioactivity of FGF2 in fibrin gel 
The fibrin gel (400 μl) was formed by mixing fibrinogen (4 mg/ml) solution with either 500 
ng free FGF2 or the coacervate containing 50 μg PEAD, 10 μg heparin and 500 ng of FGF2, 
and thrombin in the basal medium. The gel was incubated at 37°C for 30 min and overlaid with 
600 μl basal medium. After 24 h incubation, FGF2 in the medium was precipitated by addition of 
trichloroacetic acid (TCA) and centrifuged at 12,100g for 10 min. Ice-cold acetone was utilized 
to wash out residual TCA. The pellets were dissolved in sample buffer for SDS-PAGE and 
western blotting.  
Endothelial tube formation was investigated at three FGF2 dosing levels (50, 250, and 
500 ng/ml) using fibrin gel assay as described above. HUVECs (Lonza) were maintained in 
EGM-2 basal medium supplemented with growth factors according to the supplier’s instruction. 
The experimental procedures of tube formation followed a published protocol (19). Briefly, 8x104 
cells (passage 7) were mixed with fibrinogen solution containing FGF2 (50, 250 or 500 ng) or 
the same amount of FGF2 in the coacervate. After addition of thrombin, the whole solution was 
gelled at 37°C for 30 min. The gel was last overlaid with 600 μl of the basal medium to provide 
the basic nutrient. After incubation for 3 days, the phase contrast images were taken by a 
microscope. 
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Chemotaxis of pericytes induced by coacervate 
Human pericytes were isolated following the established method [153]. For the 
chemotaxis experiment, 1.0x104 pericytes (passage 7) were added in Transwell® inserts (pore 
size of 8 μm) and placed in a 24-well plate containing blank solution, delivery vehicle, 100 ng of 
FGF2 or the coacervate having 100 ng of FGF2. After incubation for 12 h, nonmigrating cells 
were removed with cotton swabs and migrating cells were stained by Quant-iT™ PicoGreen® 
(Invitrogen). The fluorescent images were taken by an inverted microscope Eclipse Ti (Nikon). 
Animal care and subcutaneous injection 
Male Balb/cJ mice (Jackson Laboratory) with an average age of 6-7 weeks were used 
and cared for in compliance with a protocol approved by the Institutional Animal Care and Use 
Committee of the University of Pittsburgh. Under isoflurane anesthesia, 65 μl of saline, delivery 
vehicle (500 μg of PEAD and 100 μg of heparin), free FGF2 (500 ng of FGF2) or the coacervate 
(500 μg of PEAD, 100 μg of heparin and 500 ng of FGF2) was subcutaneously injected in the 
left back of the mice through a 31G insulin needle. The right back which did not receive injection 
served as the contralateral control. All groups contained 4 to 8 mice. 
Hemoglobin quantification  
            The animals were sacrificed at post-injection week 1, 2 and 4. The subcutaneous tissue 
having a dimension of 1.5 cm x 1.5 cm was harvested at the injection site and the contralateral 
site. The hemoglobin in the harvested tissue was extracted by addition of in 500 μl of the 
hemolysis buffer containing 17 mM of Tris-HCl (pH 7.4) and 0.75 wt% ammonium chloride and 
incubation for 24 h. The absorbance at 410 nm corresponding to the hemoglobin Soret band 
was recorded by a SynergyMX plate reader (Biotek) [154]. All values were normalized to that of 
the saline injection.  
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Immunofluorescent staining 
            The harvested subcutaneous tissue was embedded and frozen in Tissue-Tek OCT 
compound (Sakura Finetek USA). Sections of 5 µm thickness were cut with a cryo-microtome 
and stored at -80°C. For CD31 staining, a rat anti-mouse CD31 monoclonal antibody (BD 
Biosciences) was applied first followed by a Cy3-conjugated anti-rat IgG antibody (Invitrogen). 
For α-SMA staining, a FITC-conjugated anti-α-SMA monoclonal antibody (Sigma) was utilized 
according to the provided instruction. For PDGFR-β staining, a goat anti-mouse PDGFR-β 
polyclonal antibody (R&D Systems) was applied first followed by an Alexa Fluor 488-conjugated 
anti-goat IgG antibody (Invitrogen). For VWF staining, a FITC-conjugated anti-VWF antibody 
(US Biological) was used. For desmin staining, a rabbit anti-desmin polyclonal antibody (sigma) 
was applied first followed by an Alexa Fluor 594-conjugated anti-rabbit IgG antibody 
(Invitrogen). For calponin staining, a rabbit anti-mouse calponin-1 monoclonal antibody 
(Millipore) was applied first followed by an Alexa Fluor 594-conjugated anti-rabbit IgG antibody. 
All slides were last counterstained with DAPI (Invitrogen). The fluorescent images were taken 
using a Fluoview 500 Confocal microscope (Olympus). 
Quantitative analysis of immunofluorescent staining 
For quantification of CD31- or α-SMA-positive cells, six low magnification (200X) fields 
containing the highest number of CD31- or α-SMA-positive cells were selected for each group 
following a previously published criteria [155]. The number of CD31- or α-SMA-positive cells in 
the field were counted and confirmed by DAPI-positive nuclei. The value was divided by the 
area of the tissue and normalized to that of the saline group. For comparison of the number and 
the size of blood vessels, CD31-positive blood vessels in three low magnification (200X) fields 
of the free FGF2 or the coacervate group were determined and measured by NIS-Elements 
software (Nikon).  
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Statistical analysis 
Student’s t-test was used for pair comparison between the coacervate and free FGF2 for 
the chemotaxis experiment or free FGF2 for the in vivo experiment. ANOVA followed by post-
hoc Bonferroni test was utilized to compare the number of CD31- and α-SMA-positive cells 
between all conditions. Data is presented as mean ± standard deviations. *p value < 0.05; **p 
value < 0.01. 
 
 
 
 
4.1.3      Results 
Interactions between PEAD, heparin and FGF2 
This research used poly(ethylene argininylaspartate diglyceride) (PEAD) that consists of 
aspartic acid, arginine and diglyceride moieties. The amino and guanidine groups were 
positively charged under physiological conditions and enable PEAD to interact strongly with 
heparin, the most negatively-charged glycosaminoglycan. This charge interaction was employed 
to load heparin-binding growth factors into the delivery vehicle. PEAD lowered the solubility of 
[heparin:FGF2] complex in water by forming a coacervate through charge interactions (Fig. 18). 
[PEAD:heparin:FGF2] coacervates aggregated over time and settled at the bottom of the vessel 
as an oil droplet after 24 h of standing. The droplet was easily resuspended by agitation, which 
returns the solution to the turbid state. Scanning electron microscopy revealed that the 
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morphology of the [PEAD:heparin:FGF2] mainly consists of globular domains that can fuse with 
each other to form strands (Fig. 19).  
 
 
Figure 18. The three components dissolve well in water individually as represented here by 
heparin. Adding FGF2 induces no apparent changes in solubility. Upon addition of PEAD, the 
solution turns cloudy. Charge neutralization between the polycation and heparin forms the 
[PEAD:heparin:FGF2] coacervate which is insoluble in the aqueous solution, enabling local 
delivery of FGF2. Upon standing for 24 h, the coacervate aggregates to the bottom of the tube.  
 
 
Figure 19. SEM micrograph revealed that [PEAD:heparin:FGF2] mainly consisted of globular 
domains that fuse together. The globular nature of the coacervate is more distinguishable at 
higher magnification. Scale bars: 10 μm (low magnification) and 1 μm (high magnification).  
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An effective delivery vehicle should have high loading efficiency in addition to controlled 
release of the cargo. We tested the loading efficiency of the delivery vehicle by western blot. 
Following the centrifugation of the coacervate, the amount of FGF2 in the supernatant and the 
coacervate were compared to the amount in the original loading solution. Comparison of the 
band intensity of western blot using NIH ImageJ found no FGF2 in the supernatant. 
Furthermore, the amount of FGF2 in the coacervate when 100, 500, and 1,000 ng of FGF2 was 
used (Fig. 20) is statistically the same as the loading solution suggesting nearly 100% loading 
efficiency. We expect the loading efficiency will also be near 100% for higher amount of growth 
factors because of the large excess of heparin relative to growth factor. We ended the test at 
1,000 ng because the subsequent in vivo examination used only 500 ng FGF2. 
 
 
                                                        
 
Figure 20. The loading efficiency is >95% for FGF2 (500 μg PEAD, 100 μg heparin, FGF2 
range tested: 100 - 1000 ng). Western blot demonstrated that the intensity of the coacervate 
and the loading solution is the same. S: FGF2 in the supernatant after centrifugation. C: FGF2 
in the settled coacervates. L: total amount of FGF2 in the loading solution. 
 
Most free growth factors degrade quickly in vivo; therefore bolus injection has very low 
efficacy. Because heparin can protect growth factors from proteolytic cleavage, we examined if 
heparin in the coacervate retains its protective capability. When treated with a broad spectrum 
protease, trypsin, all free FGF2 was degraded within 0.5 h (Fig. 21, column I). On the other 
hand, heparin protected FGF2 from trypsin digestion (Fig. 21, column II) and so did the 
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coacervate (Fig. 20, column III). An average of 86.1% of FGF2 was present in the coacervate 2 
h after trypsin treatment demonstrating that heparin retained its protective effect. 
 
                                                           (I)                (II)            (III) 
Figure 21. Protection from proteolysis by the coacervate. FGF2 and trypsin (mass ratio 1:200) 
was incubated for 30 min or 2 h at 37°C. The results indicated that free FGF2 (I) was completely 
degraded within 0.5 h. On the other hand, heparin (II) and the coacervate (III) protected FGF2 
from degradation for at least 2h. 
 
In order to examine the ability of the coacervate to localize FGF2 in the tissue, we used 
fibrin gel to mimic the in vivo environment. The gel was overlaid with medium and the amount of 
FGF2 in the medium was determined after 24 h by western blotting. A significantly lower amount 
of FGF2 was detected in the medium of the coacervate group indicating that the coacervate can 
effectively localize FGF2 (Fig. 22). To investigate potential endothelial response to FGF2 
released from the coacervate, human umbilical vein endothelial cells (HUVECs) were 
embedded in the fibrin gel as previously described [156]. Different concentrations of FGF2 were 
tested for their ability to induce tube formation.  After three days, free FGF2 did not induce tube 
formation at any concentration (Fig 23). Most cells were round with a few spread-out cells 
scattered throughout the gel. On the other hand, HUVECs in the coacervate groups formed a 
clearly visible network of nascent endothelial tubes at 250 and 500 FGF2 ng/ml FGF2. This 
indicated that the FGF2 coacervate may induce more potent localized angiogenesis in vivo than 
free FGF2.  
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Figure 22. The coacervate localized FGF2 release in fibrin gel. Fibrin gels were prepared with 
free FGF2 or FGF2-containing coacervate. The amount of FGF2 in the medium was determined 
by western blot. Less FGF2 was present in the medium of the coacervate group suggesting that 
FGF2 was localized better in the fibrin gel than the free FGF2 group. 
 
 
Figure 23. Endothelial tube formation in fibrin gels. HUVECs mixed with free FGF2 (50, 250 or 
500 ng/ml) or the same amount of FGF2 in the coacervate were encapsulated in the fibrin gel. 
After incubation of 3 days, the coacervate induced extensive tube network formation at 250 and 
500 ng/ml of FGF2. On the contrary, FGF2 alone induced sparse tube formation at all growth 
factor concentrations. Scale bar: 100 μm. 
 
Free 
FGF2 
FGF2 
coacervate 
50 ng/ml 250 ng/ml 500 ng/ml 
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The bioactivity of FGF2 was further examined by using mural cells that are important in 
the stabilization of blood vessels. Pericytes are actively involved in early angiogenesis, and their 
recruitment is critical to stabilize the newly formed vessels. Chemotaxis assays using pericytes 
revealed that both free FGF2 and the coacervate had higher chemotactic activities than the 
control groups which were basal medium and the delivery vehicle. More importantly, pair-wise 
comparison between the coacervate and free FGF2 yielded a p-value lower than 0.05 revealing 
a higher chemotactic activity of FGF2 released from the coacervate (Fig. 24).  
 
                                                I                                                       III 
    
Figure 24. Chemotaxis of pericytes by the coacervate. After incubation for 12 h, migrated 
pericytes were stained by PicoGreen. Quantitative comparison suggested that the coacervate 
induced significantly higher extent of chemotaxis than free FGF2 (254±44 vs. 108±14 per mm2, 
p<0.05, Student’s t-test). Scale bar: 100 μm.  
[PEAD:Heparin:FGF2] promotes more potent angiogenesis than free FGF2 
In order to examine the in vivo efficacy of the coacervate, the coacervate containing 500 
ng of FGF2 was injected subcutaneously in the back of male BALB/cJ mice and compared its 
angiogenic capability to that of saline, delivery vehicle and 500 ng of free FGF2 respectively 
(Fig. 25). Macroscopic observation of the coacervate group revealed extensive formation of 
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blood vessels at the injection site whereas the contralateral site showed no difference from 
normal tissue (Fig. 26). Hematoxylin and eosin staining revealed that the gross appearance of 
the saline and delivery vehicle groups are indistinguishable suggesting the delivery vehicle itself 
had no angiogenic effect (Fig. 27). Free FGF2 induced aggregation of nucleated cells, but few 
blood vessels were identified. On the contrary, the coacervate showed significant blood vessel 
formation with closed circles of nucleated cells surrounded by muscle bundles (arrow). The 
lumen of vessel was filled with red cells further supporting the function of the nascent blood 
vessels. 
 
 
 
Figure 25. Subcutaneous injection of FGF2 coacervate 
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                                      Injection site                                Contralateral site 
       
Figure 26. Macroscopic observation of subcutaneous tissue showed that the coacervate clearly 
induced new blood vessel formation at the injection site (2-week pictures from the same 
mouse).  
 
Fig 27. Hematoxylin and eosin staining of subcutaneous tissues after 4 weeks. For the saline, 
delivery vehicle and free FGF2 groups, there were no clear growth of vasculature in the 
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subcutaneous region. The coacervate group, on the contrary, revealed the feature of blood 
vessel which had a closed inner layer of nucleated cells surrounded by smooth muscle bundles 
(arrow). Scale bar: 50 μm. 
 
As an indirect measure of blood vessel density, the amount of hemoglobin in the tissue 
at the injection site at 1, 2, and 4 week post-injection was quantified using a previously 
published method [157].  All the groups had no significant difference at week 1. The coacervate 
group had higher amounts of hemoglobin than any other groups at week 2 and 4 (Fig. 28). On 
the other hand, bolus injection of free FGF2 showed no statistical difference in hemoglobin 
content from saline and delivery vehicle groups at any time point. After 4 weeks, the coacervate 
group still exhibited a significantly higher amount of hemoglobin than all control groups 
suggesting the long term stability of the newly formed blood vessels and the bioactivity of FGF2 
released from the coacervate. The ratio of hemoglobin at the injection and contralateral site 
revealed that angiogenic responses were spatially controlled for the coacervate whereas the 
free FGF2 group showed no difference (Fig. 29). This correlated well with the macroscopic 
observation that the angiogenic activity of the coacervate was localized at the injection site. For 
the free FGF2 group, the ratio was close to 1 at every time point and was significantly lower 
than that of the coacervate after 2 weeks. This combined with the insignificant change of 
hemoglobin from saline control suggested that bolus injection of 500 ng FGF2 had little 
angiogenic potency. Overall, the histological examination demonstrated the high efficacy of the 
coacervate in promoting angiogenesis and the spatial control of FGF2 release from the 
coacervate. 
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Fig 28. Hemoglobin quantification compared the extent of angiogenesis between different 
groups. The result suggested that the coacervate group had a higher amount of hemoglobin 2 
weeks post-injection whereas free FGF2 did not have statistical difference between the saline 
and delivery vehicle groups. This difference lasted at least for 4 weeks. (mean± s.d., n=4-8 for 
each condition) Normalized to the saline group. One-way ANOVA followed by Bonferroni 
correction was applied for multiple comparisons. *p<0.05, ** p<0.01.  
 
 
Figure 29. The ratio of hemoglobin at the injection sites and the contralateral sites. For the 
coacervate, the ratio was significantly higher than that of the free FGF2 group. The result 
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explained that FGF2 was well localized at the injection site by the delivery vehicle. Student’s t-
test was used as a statistical tool. *p<0.05, ** p<0.01. 
[PEAD:Heparin:FGF2] stimulates proliferation of endothelial and mural cells 
            The more potent angiogenesis induced by the coacervate warranted further study on the 
effects of the released FGF2 on cell functions. Two specific markers closely associated with 
angiogenesis was utilized: CD31 for endothelial cells and α-smooth muscle actin (α-SMA) for 
mural cells (pericytes or smooth muscle cells). Both the coacervate and free FGF2 promoted 
more endothelial cells (CD31-positive) than saline and the delivery vehicle qualitatively 1 week 
post-injection, (Fig. 30). This was attributed to the proliferation of endothelial cells stimulated by 
FGF2. On the other hand, only a small number of mural cells (α-SMA-positive) were present in 
all groups. After 2 weeks, higher number of endothelial cells can still be found at the presence of 
the coacervate and free FGF2. However, the coacervate also induced a significant amount of 
mural cells. More importantly, the blood vessels in the coacervate group were well organized 
into circles of endothelial cells surrounded by mural cells. This difference was even more 
pronounced after 4 weeks. Compared to the coacervate, the other three groups were similar in 
that most endothelial cells lacked support by mural cells. Higher magnifications of the vessels in 
the coacervate group showed distinctive structure of blood vessels with aligned endothelial cells 
closely associated and sounded by mural cells (Fig. 31).   
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Figure 30. Representative confocal micrographs showed the distribution of blood-vessel 
associated markers CD31 (endothelial cell, red) and α-SMA (mural cell, green) of each group at 
three time points. Both the free and coacervate FGF2 groups revealed a higher quantity of 
endothelial cells than saline control after 1 week, but only the coacervate induced an increase of 
α-SMA expression after 2 weeks. The circular vessel-like structures were observed in the field.  
After 4 weeks, more endothelial and mural cells were present in the coacervate group 
demonstrating the long term efficacy of the FGF2 coacervate. Scale bar: 50 μm.  
 81 
 
Figure 31. High magnification revealed the maturation of the blood vessels induced by the 
coacervate. The endothelial tubes were clearly surrounded by mural cells. Scale bar: 50 μm.  
Quantification of the endothelial and mural cells was consistent with higher angiogenic 
potency of the coacervate. Six low magnification (200x) fields for each group were chosen to 
quantify the number of endothelial and mural cells. The result suggested that the coacervate 
increased the number of endothelial cells by 120%, 95% and 47% relative to that of the saline, 
delivery vehicle and free FGF2 (Fig. 32). All the comparisons were statistically significant with p 
values lower than 0.01 supporting the coacervate induced more proliferation of endothelial cells. 
The free FGF2 group had more CD31-positive cells than the saline group (p<0.01); whereas the 
delivery vehicle group showed no difference from the saline group (p=0.81) revealing that the 
delivery vehicle itself had little effect to the proliferation of endothelial cells. More striking 
difference was the number of mural cells. Significant amount of mural cells were observed in the 
coacervate group. The quantification of mural cells demonstrated that the coacervate group was 
6.71, 3.39 and 2.02 folds higher than that of the saline, delivery vehicle and free FGF2 groups 
respectively (p< 0.01 for all comparison). Again, the free FGF2 group induced more mural cells 
than saline (p<0.05), but the delivery vehicle had no difference from saline (p=0.89). 
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Figure 32. Comparison of CD31 and α-SMA expression in the 4 injected groups. The number of 
endothelial cells in the coacervate group was higher than those of the control groups by 47% to 
120%. More significantly, the number of mural cells in the coacervate group was 2.02 folds of 
that in the free FGF2 group. One-way ANOVA followed by Bonferroni correction, *p<0.05; 
**p<0.01. 
 
Furthermore, the number and the size of the blood vessels in free FGF2 and coacervate 
groups was compared by counting CD31-positive blood vessels and measuring their area 
according to a previously published procedure [158]. The average number of blood vessels in 
the coacervate group was higher than that of the free FGF2 group (63.5±3.6 vs. 46.0±7.7 per 
mm2, p<0.05) (Fig. 33). This is consistent with the above data that showed the coacervate group 
induced more vascular cell proliferation and the injection site contains more hemoglobin (Figs. 
28, 29). Comparison of the size of the blood vessels revealed that the coacervate group had 
more blood vessels per mm2 for all three size groups including <400 μm2 (34.1 vs. 28.6), 400-
1,000 μm2 (20.6 vs. 15.9) and >1,000 μm2 (8.7 vs. 1.6). It is worth noting that blood vessels with 
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areas lager than 1,000 μm2 all had abundant α-SMA expression and are likely arterioles and 
venules. Collectively, the immunohistochemical analysis strongly supported higher angiogenic 
potency of the FGF2 coacervate. 
 
Figure 33. Comparison of the number of blood vessels in a given size range between free and 
coacervate FGF2 groups as previously described; the value represents the cumulative number 
of all the slides examined (24). The coacervate induced more blood vessel formation than free 
FGF2. Furthermore, the coacervate group contained more large vessels (>1,000μm2, likely 
associated with arterioles and venules). 
[PEAD:Heparin:FGF2] coacervate promotes neovasculature maturation by recruiting 
mural cells 
The maturity of newly formed blood vessels is critical for their stability and function. 
Thus, we studied the maturation of neovasculature induced by the coacervate from early to late 
stages of angiogenesis. For the early angiogenic process, CD31 was co-stained with a pericyte 
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specific marker, platelet derived growth factor receptor-β (PDGFR-β) [159]. The result observed 
many CD31-positive endothelial cells clustered with PDGFR-β-positive cells in the coacervate 
group 1 week post-injection (Fig. 34). On the contrary, no association of pericytes and 
endothelial cells was observed in the free FGF2 group. This difference again demonstrated the 
efficacy of the coacervate in maintaining the bioactivity of FGF2. 
 
 
Figure 34. The co-localization of CD31-positive and PDGFR-β-positive cells suggested the 
coacervate quickly recruited pericytes to interact with endothelial cells in the nascent vessels. 
This phenomenon was absent in the free FGF2 group. Scale bar: 50 μm. 
For long term vessel maturity, the markers associated with vascular functions were 
examined. Von Willebrand factor (VWF), an important protein involved in hemostasis was 
stained to show the potential of the nascent blood vessels to participate in hemostasis. It was 
found that the coacervate induced strong expression of VWF (Fig. 35). The overlap of CD31 
Free 
FGF2 
FGF2 
coacervate 
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and VWF signals indicated that the nascent endothelial cells were functional. Desmin, a 
component of intermediate filament expressed in mural cells is a widely used marker to study 
perivascular structure. Desmin was observed to co-expresse in α-SMA-positive blood vessels 
(Fig. 36). Additionally, α-SMA-negative but desmin-positive blood vessels were also found in the 
field. This likely reflected the distribution of vessel sizes and the heterogeneity of pericytes 
which had low α-SMA expression at capillary levels [160]. Calponin mediate contractile 
responses of vascular smooth muscle cells; and we co-stained this important marker with α-
SMA to evaluate the functionality of nascent blood vessels. The result showed again that more 
and larger blood vessels were induced by the coacervate than by free FGF2 (Fig. 37). Overall, 
the results of immunohistochemical analysis demonstrated that more mature vasculature was 
induced by the coacervate, which correlated well with the higher local hemoglobin concentration 
at the injection site. 
 
Figure 35. Significant co-localization (green + red = yellow) of VWF- and CD31-positive cells 
suggested that the endothelial cells in the nascent vessels can potentially participate in 
hemostasis. Scale bar: 50 μm. 
Free 
FGF2 
FGF2 
Coacervate 
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Figure 36. Both α-SMA and desmin are markers for mural cells. Their expression pattern 
revealed that larger vessels co-expressed these markers whereas smaller vessels were 
dominated by the expression of desmin (arrows). Scale bar: 50 μm. 
 
FGF2 
coacervate 
Free 
FGF2 
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Figure 37. Calponin, a calmodulin associated with vascular smooth muscle cells contraction, 
was co-stained with α-SMA to examine the potential functionality of the new blood vessels. The 
result indicated that the blood vessels in the coacervate group had abundant expression of 
calponin. In addition, the blood vessels were much larger in the coacervate group than those in 
the free FGF2 group. Scale bars: 50 μm. 
 
 
 
4.1.4      Discussion 
The goal is to develop an injectable platform that is easily administered even in a basic 
clinic. Thus, a coacervate was formed by simple mixing of three water soluble components: a 
FGF2 
coacervate 
Free 
FGF2 
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biocompatible polycation, heparin and a heparin-binding growth factor. The resultant coacervate 
has very low viscosity and is injectable via a 31 G needle (outer diameter: 0.26 mm) or a 
catheter. The loading efficiency of FGF2 is nearly 100% according to the results of both ELISA 
and western blot [151]. The coacervate delivery platform is highly effective with a low dosage of 
500 ng FGF2. In many test results reported here, there are insignificant differences between 
free FGF2, saline, and the delivery vehicle. The 500 ng dosage is much lower than what is 
commonly used in the literature. The injectability combined with high loading efficiency and 
efficacy of the coacervate may enable new opportunities of growth factor treatment for certain 
diseases such as cardiac infarct where only a small volume can be injected and wound must be 
minimal. 
Therapeutic angiogenesis via exogenous growth factors including FGF2, VEGF and 
PDGF has been examined extensively to treat human ischemic diseases [161,162] that resulted 
in huge progress in understanding of growth factor signaling and its interaction with the host. 
However, there has yet to be a clear demonstration of clinical benefits [135]. Typically, the 
treatment group showed improvement at the early stage but had no significant difference from 
the placebos in long term observation [163]. This has been attributed to the lack of stability of 
the nascent blood vessels. Current approach to solve this challenge is co-delivery of multiple 
growth factors to boost the long term stability of the neovasculature [164,165]. Often, a growth 
factor can stimulate a range of cells to accomplish physiological events such as embryonic 
development, angiogenesis, vasculogenesis, and wound healing [166,167,168]. FGF2 binding 
to FGF receptors dimerizes the receptors, activates their tyrosine kinases and triggers the 
downstream signaling pathways [169]. For endothelial cells, FGF2 is a potent mediator that can 
promote their proliferation, migration, differentiation and stimulate the expression of VEGF to 
initiate angiogenesis [170]. In addition, FGF2 can recruit pericytes to newly formed blood 
vessels [171] and promote the survival and proliferation of vascular smooth muscle cells [172]. 
Both pericytes and smooth muscle cells substantially enhance the stability of the 
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neovasculature. Consequently, mature vasculature is achievable if the bioactivity of FGF2 is 
well maintained. The challenge is that the delivery system must maintain the bioactivity of the 
growth factors and release them with appropriate spatiotemporal control. By designing the 
delivery system de novo, we developed a coacervate that maintained the bioactivity of FGF2 
well and enabled formation of mature vasculature with the controlled release of a single growth 
factor. 
 
 
 
 
4.1.5      Summary 
The current study evaluates the angiogenic activity of a heparin-based coacervate using 
a rodent model. Only one injection of the coacervate is required for sustained angiogenesis. 
Furthermore, the blood vessels formed are mature and stable to at least 4 weeks. The FGF2 
coacervate has a much higher angiogenic efficacy than free FGF2. Further investigations 
include the effectiveness of this platform in ischemic animal models and in vivo imaging of the 
blood vessels to monitor flow and potential vasoresponsiveness. Because the polyvalent charge 
interaction is critical to the formation and stability of the coacervate, we expect efficient control 
of growth factor release by tailoring charges and size of PEAD as we demonstrated in a related 
polycation [96]. It is expected this new delivery platform will be useful in the controlled release of 
many heparin-binding growth factors that control important biological functions. 
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4.2      POST-MYOCARDIAL INFARCTION ANGIOGENESIS BY FGF2 COACERVATE 
As demonstrated in the previous section, [PEAD:heparin] coacervate enhances 
angiogenic activity of FGF2 and induces neovasculature with substantial maturity. The results 
are promising; however, healthy animals have normal physiological activities and do not reflect 
the pathological environment. Consequently, I decided to investigate the utility of coacervate in 
ischemic animals. I chose a mouse myocardial infarction model because it is well established 
and widely adopted. It closely mimics human heart attack and can better verdict the usefulness 
of this novel platform clinically. 
 
 
 
 
4.2.1      Introduction 
Myocardial infarction (MI) characterized by permanent blockage of coronary artery is the 
leading cause of death in developed countries. MI results in several physiological 
consequences, including ischemia, inflammation, fibrosis and loss of cardiomyocytes, which 
collectively compromise the contractile capability of heart. Ischemia is the most serious outcome 
because without sufficient blood supply the remaining cardiomyocytes would dye and the 
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overload would cause heart failure eventually. Consequently, promoting angiogenesis is 
expected to be an effective treatment in protecting remaining cardiomyocytes. FGF2-containing 
coacervate was applied in a disease model that mimics the human MI (Fig. 38). Single injection 
of saline, delivery vehicle (500 μg of PEAD and 100 μg of heparin), free FGF2 (500 ng of FGF2) 
or FGF2 coacervate (500 μg of PEAD, 100 μg of heparin and 500 ng of FGF2) was compared to 
evaluate the efficacy of the coacervate-delivered FGF2. Histological analysis included 
hematoxylin and eosin staining for gross observation and Masson’s trichrome staining for 
fibrosis. Both staining provided valuable information about the area of infarction. Additionally, 
CD31, α-SMA and VWF staining were utilized to stain endothelial cells and mural cells to 
determine the extent of angiogenesis. Functional recovery measured by echocardiography gave 
a comprehensive evaluation to conclude the effectiveness of FGF2 coacervate in the ischemic 
heart disease. 
 
Figure. 38 Mouse acute MI model. Left anterior descending artery is ligated to induce 
myocardial infarction in BALB/cJ mice. FGF2-containg coacervates or control solutions are 
injected within 5 minutes. 
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4.2.2      Experimental section 
Acute myocardial infarction model       
The surgical procedures utilized to induce MI are briefly described below. 10-week-old 
BALB/cJ mice were intubated with a catheter for mechanical ventilation with an anesthetic gas 
mixture using a small animal ventilator. The left thoracic cavity was opened with an incision 
through the fourth intercostal space. The ribs and overlying muscle were separated and 
retracted with 5-0 silk sutures on each side of the incision. For creation of MI injury in the 
anterior wall of the left ventricle, the pericardium was cut to expose the heart, and the left 
anterior descending coronary artery was permanently ligated with an 8-0 Prolene suture. Within 
5 min, solution was injected with an insulin syringe equipped with a 30G needle into the center 
of the infarct and in the peri-infarct region (Fig. 38). A successful injection into the myocardium 
can be determined visually under a surgical microscope by the marked change in color (pink to 
grey) and the formation of a gentle bump underneath the epicardium of the injection site. Once 
the injection was complete, the chest was closed in three layers (rib-intercostal space, overlying 
muscle, and skin) with 4-0 Vicryl absorbable sutures. Each mouse was observed post-operation 
until it had recovered from the anesthesia before returning to the animal holding room. 
After 6 weeks, each mouse was euthanized with a deep anesthesia of isoflurane 
followed by tail vein injection of 1M KCl for diastolic arrest of the heart. It was important to arrest 
the heart in diastole because the geometry of the left ventricle needs to be preserved to 
accurately determine the area of the engraftment and dimensions of the LV for histological 
assessment. The heart was harvested and frozen in liquid nitrogen for histological and 
immunofluorescent examination. 
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Echocardiography 
Echocardiograms were utilized to assess LV dimensions and systolic function at 2 time 
points (2 weeks and 6 weeks), as previously described [173]. Two-dimensional images were 
obtained at the midpapillary muscle level. Left ventricular end-diastolic area (EDA) and end-
systolic area (ESA) were measured from short-axis images of the LV, and both LV end-diastolic 
dimension (EDD) and end-systolic dimension (ESD) were measured from at least 6 consecutive 
beats via M-mode tracing. To measure LV contractility, fractional area change (FAC) was 
calculated as FAC(%) = [(EDA - ESA) / EDA] x 100. 
Immunofluorescent staining 
The harvested subcutaneous tissue was embedded and frozen in Tissue-Tek OCT 
compound (Sakura Finetek USA). Sections of 8 µm thickness were cut with a cryo-microtome 
and stored at -80°C. For CD31 staining, a rat anti-mouse CD31 monoclonal antibody (BD 
Biosciences) was applied first followed by a Cy3-conjugated anti-rat IgG antibody (Invitrogen). 
For α-SMA staining, a FITC-conjugated anti-α-SMA monoclonal antibody (Sigma) was utilized 
according to the provided instruction. For VWF staining, a FITC-conjugated anti-VWF antibody 
(US Biological) was used. All slides were last counterstained with DAPI (Invitrogen). The 
fluorescent images were taken using a Fluoview 500 confocal microscope (Olympus). 
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4.2.3      Results and discussion 
FGF2 coacervate preserved ventricular function revealed by echocardiography 
Our prior study (section 3.1) indicated that 500 ng of FGF2 delivered by [PEAD:heparin] 
induced significant angiogenesis and generated mature vessels. To examine its effect in 
ischemic heart diseases, identical amount of FGF2 coacervate was applied in an acute 
myocardial infarction model. In this model, the left anterior artery was ligated to create infarction 
followed by intramyocardial injection of FGF2 coacervate (n=6). The controls were saline (n=7), 
delivery vehicle (n=5) and free FGF2 (n=7). After 2 weeks, echocardiographic assessment 
observed the highest mean EDA (17.8±2.0mm2) and ESA (12.5±1.6mm2) in the saline group 
(Fig. 39). ANOVA-Tukey’s HSD test showed that both values were significantly higher than 
those of the healthy controls (baseline). It suggested successful induction of MI leading to heart 
dilation. Statistically lower FAC 29.5±4.2%) of the saline group also pointed out that the 
contractile function was compromised. For the remaining groups, the FGF2 coacervate group 
had a mean ESA (9.1±1.6mm2) and EDA (15.6±2.5mm2) values lower than those of the delivery 
vehicle group (ESA 12.3±1.3mm2; EDA 17.2±1.2mm2) and the free FGF2 group (ESA 
12.8±1.9mm2; EDA 19.2±1.7mm2). Furthermore, the FAC of the FGF2 coacervate group being 
41.8±3.7% was higher than those of the delivery vehicle group (2864±3.2%) and the free FGF2 
group (33.2±7.0%). Pairwise comparison of ESA, EDA and FAD between the free FGF2 and the 
FGF2 coacervate groups all have p values lower than 0.01. Consequently, echocardiographic 
assessment concluded that FGF2 coacervate preserved better left ventricular function that free 
FGF2 2 weeks post-infarction. 
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Figure 39. ESA and EDA data indicated that the left ventricle was not dilated in the coacervate 
group at 2 weeks, whereas all 3 control groups showed dilation indicating the coacervate 
delayed the onset of pathological remodeling.  FAC data at 6 weeks indicated that heart 
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contractility of the coacervate group was 50% and 88% higher than free FGF2 and saline 
injection respectively. One-way within-subjects ANOVA followed by Tukey’s HSD test was 
applied to compare individual treatment. ** indicated p value lower than 0.01 when FGF2 
coacervate group was compared with all 3 control groups. 
 
At 6 weeks, all experimental groups had significantly higher ESA and EDA and lower 
FAC than the healthy controls showing infarct reduced left ventricular function as time 
progresses. Among all experimental groups, the FGF2 coacervate group still had the lowest 
ESA (13.1±2.1mm2) and EDA (19.8±1.4mm2) and the highest FAC (34.1±6.2%), consistent with 
the result at 2 week; one-way within-subjects ANOVA followed by Tukey’s HSD test suggested 
that these values were statistically different from those of the saline, delivery vehicle and free 
FGF2 groups. It pointed out that FGF2 coacervate delayed heart dilation and preserved 
contractile function. On the other hand, the free FGF2 group had no difference with the saline 
and delivery vehicle groups. Consequently, the result of echocardiography concluded that 500 
ng of free FGF2 did not show significant effects in infarcted hearts whereas FGF2 delivered by 
the coacervate was effective enough to show benefit.  
FGF2 coacervate preserved cardiac structure at early timepoint 
The histological analysis compared individual group at tissue level. For saline injection, 
hematoxylin and eosin staining showed that myocardial infarction seriously damaged the 
structure of cardiac fibers (Fig. 40). Compared to tissue at the remote zone, significant 
difference indicated that almost all cardiomyocyte fibers were lost in the infarct zone after 2 
weeks. Actinin staining that recognized cardiomyocytes also indicated their loss caused by MI 
(Fig. 41). FGF2 coacervate, however, preserved certain cardiac structure in the infarct zone 
while it was not seen in delivery vehicle and free FGF2 injection (Fig. 42); these included actinin 
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staining further confirmed that infarction caused cardiomyocyte death at the infarct zone (Fig. 
43). FGF2 coacervate was able to reduce cardiomyocyte death more effectively. 
 
 
Figure 40. Hematoxylin and eosin staining revealed MI caused cardiomyocyte loss. Scale bar: 
100 μm. 
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Figure 41. Actinin staining (green color) that labeled cardiomyocytes showed cardiomyocyte 
loss in the infarction and border zones. Scale bar: 50 μm. 
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Figure 42. Hematoxylin and eosin staining indicated FGF2 coacervate group had thicker heart 
wall compared to [PEAD:heparin] and free FGF2 groups. Scale bar: 100 μm. 
 
 
 100 
 
Figure 43. Actinin staining pointed out that more viable cardiomyocytes existed in the infarct 
zone for the FGF2 coacervate group. Scale bar: 50 μm. 
FGF2 coacervate had long term effect to reduce fibrosis 
Fibrosis is a result of pathological remodeling after myocardial infarction, in which fibrillar 
collagen plays a major structural role. Excess fibrosis stiffens the heart wall and lowers 
contractility. To evaluate the effect of FGF2 coacervate in fibrosis, Masson’s trichrome staining 
was used to compare each group 6 weeks post-MI (Fig. 44). The staining showed that all 
experimental groups contained dense collagen fiber formation at the infarct zone along with 
heart wall thinning (data not shown). No difference was observed between all groups. At the 
border zone, nevertheless, the results revealed that the FGF2 coacervate group had less fibrotic 
tissue than the saline, delivery vehicle and free FGF2 groups. Hematoxylin and eosin staining 
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further confirmed that FGF2 coacervate preserved cardiac structure better at the border zone 
(Fig. 45). 
 
Figure 44. Masson’s trichrome staining suggested FGF2 coacervate group had less fibrosis in 
the border zone compared to three control groups. Scale bar: 100 μm. 
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Figure 45. Hematoxylin and eosin staining showed that more cardiomyocytes were preserved in 
the border zone for the FGF2 coacervate group. Scale bar: 100 μm. 
FGF2 coacervate promoted more blood vessel formation 
 When bioactivity is maintained, FGF2 promotes neovasculature formation and is 
expected to reduce damage caused by ischemic condition. The extent of angiogenesis was 
examined by staining of blood vessel-associated markers, VWF and CD31 for endothelial cells, 
and α-SMA for mural cells (Fig. 46). For CD31 staining, the results showed that at the border 
zone, more blood vessels were observed for the FGF2 coacervate group. Its co-localization with 
VWF supported that these vessel were anatomically functional. Qualitatively, the number of 
vessels was higher and the size was larger. Co-staining of α-SMA and CD31 revealed 
vasculature at the anterior wall of the left ventricle. The result demonstrated that α-SMA and 
CD31 double positive vessels were clearly observed in the FGF2 coacervate group but not the 
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free FGF2 group (Fig. 47). It is possible that FGF2 coacervate preserved or protected larger 
vessels whereas free FGF2 was not effective enough to show this effect. However, it was also 
possible that these vessels grew from smaller vessels by stimulation of FGF2 coacervate. More 
study  be necessary to address this result. 
 
 
Figure 46. VWF (green color) and CD31 (red color) staining revealed FGF2 coacervate 
promoted more angiogenesis in the border zone than free FGF2. Scale bar: 50 μm. 
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Figure 47. α-SMA (green color) and CD31(red color) staining demonstrated FGF2 coacervate 
perserved more angiogenesis at the anterior wall than free FGF2. Scale bar: 50 μm. 
 
 
 
4.2.4      Summary 
Successful angiogenesis can bring significance for infracted heart in which blood supply 
is critical for survival of remaining cardiomyocytes. When FGF2 coacervate was injected in the 
infract region, the effectiveness was demonstrated by delayed ventricular dilation and preserved 
cardiac function. The better contractile function is likely due to angiogenic activity of FGF2 
and/or its ability of cardioprotection. Future study focusing on tailoring the dosage of FGF2 will 
be necessary to further evaluate the benefit of the coacervate in an ischemic heart. 
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5.0     CONCLUSION 
Maximizing the bioactivity and prolonging the activity are critical for the success of 
growth factor therapy. A coacervate-based platform that mimics the binding between heparin, 
FGF and FGFR has been demonstrated to effectively enhance the bioactivity of growth factors 
and achieve promising outcomes in animal studies. Since heparin has high affinity to a variety of 
growth factors, this platform is expected to deliver different growth factors and has great utility in 
regenerative medicine. To our best knowledge, this is the first coacervate-based platform 
applied in controlled release of growth factors. Future study on its utility in translational medicine 
can include several directions: 
Fundamentally, how [PEAD:heparin] coacervate enhances the bioactivity of heparin-
binding factors is not fully understood. According to prior research, the condensation of growth 
factors by heparin enables more growth factors to interact with their receptors simultaneously. 
This so called polyvalency can amply the downstream signaling and cause heparin-bound 
growth factors to be more potent than free factors. It is possible that the interaction between 
PEAD and heparin further condenses heparin-binding factors and consequently strengthens the 
polyvalent effect. To test this hypothesis, soluble [PEAD:heparin:growth factor] complex has to 
be isolated and its bioactivity has to be examined by in vitro or in vivo assays. In addition, it is 
also possible that growth factors that bind to [PEAD:heparin] coacervate has distinct 
conformation from the free or heparin-bound factors. Bioinformatics tools that model the 
macromolecular interaction are able to provide some information from the structural aspect. 
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For therapeutic angiogenesis, only one dose of FGF2 has been tested in both 
subcutaneous and MI models. We would like to compare different dosage of FGF2 in order to 
obtain the best outcome and also understand the therapeutic window of FGF2 coacervate. 
Furthermore, the half-lives of FGF2 delivered by [PEAD:heparin] coacervate which are also 
valuable information can be measured by biochemical or molecular biological methods. Lastly, 
tissue repair and regeneration always involve several pathways. FGF2 can be co-delivered with 
another heparin-binding factor that targets a different pathway, for example anti-inflammation or 
stem cell recruitment. We would expect that the synergistic effect can contribute to functional 
improvement significantly.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 107 
 
REFERENCES 
 
1. Roger VL, et al. (2011) Heart disease and stroke statistics—2011 update: a report from the 
American Heart Association Circulation 123(4):e18-e209. 
2. http://www.heart.org 
3. Risau W (1997) Mechanisms of angiogenesis. Nature 386(6626):671-674. 
4. Carmeliet P, et al. (1996) Abnormal blood vessel development and lethality in embryos 
lacking a single VEGF allele. Nature 380(6573):435-439. 
5. Gale NW & Yancopoulos GD (1999) Growth factors acting via endothelial cell-specific 
receptor tyrosine kinases: VEGFs, Angiopoietins, and ephrins in vascular development. Genes 
& Development 13(9):1055-1066. 
6. Wijelath ES, et al. (2006) Heparin-II domain of fibronectin is a vascular endothelial growth 
factor-binding domain. Circulation Research 99(8):853-860. 
7. Takeshita S, et al. (1994) Therapeutic angiogenesis. A single intraarterial bolus of vascular 
endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. The 
Journal of Clinical Investigation 93(2):662-670. 
8. Lee RJ, et al. (2000) VEGF gene delivery to myocardium: deleterious effects of unregulated 
expression. Circulation 102(8):898-901. 
9. Hacein-Bey-Abina S, et al. (2003) LMO2-associated clonal T cell proliferation in two patients 
after gene therapy for SCID-X1. Science 302(5644):415-419. 
10. Taniyama Y, et al. (2002) Local delivery of plasmid DNA into rat carotid artery using 
ultrasound. Circulation 105(10):1233-1239. 
11. Nguyen DN, Green JJ, Chan JM, Langer R, & Anderson DG (2009) Polymeric materials for 
gene delivery and DNA vaccination. Advanced Materials 21(8):847-867. 
12. Williams PD & Kingston PA (2011) Plasmid-mediated gene therapy for cardiovascular 
disease. Cardiovascular Research 91(4):565-576. 
13. Lazarous DF, et al. (1997) Pharmacodynamics of basic fibroblast growth factor: route of 
administration determines myocardial and systemic distribution. Cardiovascular Research 
36(1):78-85. 
 108 
 
14. Bethel A, Kirsch JR, Koehler RC, Finklestein SP, & Traystman RJ (1997) Intravenous basic 
fibroblast growth factor decreases brain injury resulting from focal ischemia in cats. Stroke 
28(3):609-616. 
15. Laham RJ, et al. (1999) Intracoronary and intravenous administration of basic fibroblast 
growth factor: myocardial and tissue distribution. Drug Metabolism and Disposition 27(7):821-
826. 
16. Losordo DW & Dimmeler S (2004) Therapeutic angiogenesis and vasculogenesis for 
ischemic disease. Circulation 109(22):2692-2697. 
17. Takahashi K & Yamanaka S (2006) Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663-676. 
18. Maherali N, et al. (2007) Directly Reprogrammed Fibroblasts 
Show Global Epigenetic Remodeling and Widespread Tissue Contribution. Cell Stem Cell 
1(1):55-70. 
19. Leeper NJ, Hunter AL, & Cooke JP (2010) Stem cell therapy for vascular regeneration. 
Circulation 122(5):517-526. 
20. Meller R (2009) The Role of the Ubiquitin proteasome system in ischemia and ischemic 
tolerance. The Neuroscientist 15(3):243-260. 
21. Brevetti G, Giugliano G, Brevetti L, & Hiatt WR (2010) Inflammation in peripheral artery 
disease. Circulation 122(18):1862-1875. 
22. Marzouk SAM, Buck RP, Dunlap LA, Johnson TA, & Cascio WE (2002) Measurement of 
extracellular pH, K+, and lactate in ischemic heart. Analytical Biochemistry 308(1):52-60. 
23. Mehta JL & Li DY (1999) Inflammation in ischemic heart disease: Response to tissue injury 
or a pathogenetic villain? Cardiovascular Research 43(2):291-299. 
24. Le KN, et al. (2009) Vascular regeneration by local growth factor release is self-limited by 
microvascular clearance. Circulation 119(22):2928-2935. 
25. Yancopoulos GD, et al. (2000) Vascular-specific growth factors and blood vessel formation. 
Nature 407(6801):242-248. 
26. Park JE, Keller GA, & Ferrara N (1993) The vascular endothelial growth factor (VEGF) 
isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of 
extracellular matrix-bound VEGF. Molecular Biology of the Cell 4(12):1317-1326. 
27. Ruhrberg C, et al. (2002) Spatially restricted patterning cues provided by heparin-binding 
VEGF-A control blood vessel branching morphogenesis. Genes & Development 16(20):2684-
2698. 
28. Olsson A-K, Dimberg A, Kreuger J, & Claesson-Welsh L (2006) VEGF receptor signalling ? 
in control of vascular function. Nat Rev Mol Cell Biol 7(5):359-371. 
 109 
 
29. Soker S, Takashima S, Miao HQ, Neufeld G, & Klagsbrun M (1998) Neuropilin-1 is 
expressed by endothelial and tumor cells as an isoform-specific receptor for vascular 
endothelial growth factor. Cell 92(6):735-745. 
30. Kawamura H, et al. (2008) Neuropilin-1 in regulation of VEGF-induced activation of 
p38MAPK and endothelial cell organization. Blood 112(9):3638-3649. 
31. Tongers J, Roncalli JG, & Losordo DW (2008) Therapeutic angiogenesis for critical limb 
ischemia. Circulation 118(1):9-16. 
32. Hedman M, et al. (2003) Safety and feasibility of catheter-based local intracoronary vascular 
endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent 
restenosis and in the treatment of chronic myocardial ischemia. Circulation 107(21):2677-2683. 
33. Ripa RS, et al. (2006) Intramyocardial injection of vascular endothelial growth factor-A165 
plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients 
with severe chronic ischaemic heart disease. European Heart Journal 27(15):1785-1792. 
34. Alfranca A (2009) VEGF therapy: a timely retreat. Cardiovascular Research 83(4):611-612. 
35. Yla-Herttuala S, Rissanen TT, Vajanto I, & Hartikainen J (2007) Vascular endothelial growth 
factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll 
Cardiol 49(10):1015-1026. 
36. Tafuro S, et al. (2009) Inducible adeno-associated virus vectors promote functional 
angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. 
Cardiovascular Research 83(4):663-671. 
37. Ornitz DM, et al. (1996) Receptor specificity of the fibroblast growth factor family. Journal of 
Biological Chemistry 271(25):15292-15297. 
38. Zhang X, et al. (2006) Receptor specificity of the fibroblast growth factor family. Journal of 
Biological Chemistry 281(23):15694-15700. 
39. Venkataraman G, Raman R, Sasisekharan V, & Sasisekharan R (1999) Molecular 
characteristics of fibroblast growth factor–fibroblast growth factor receptor–heparin-like 
glycosaminoglycan complex. Proceedings of the National Academy of Sciences 96(7):3658-
3663. 
40. Sawada A, et al. (2001) Fgf/MAPK signalling is a crucial positional cue in somite boundary 
formation. Development 128(23):4873-4880. 
41. Werner S, et al. (1992) Large induction of keratinocyte growth factor expression in the 
dermis during wound healing. Proceedings of the National Academy of Sciences 89(15):6896-
6900. 
42. Tigges U, Hyer EG, Scharf J, & Stallcup WB (2008) FGF2-dependent neovascularization of 
subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages. 
Development 135(3):523-532. 
 110 
 
43. Vitorino P & Meyer T (2008) Modular control of endothelial sheet migration. Genes & 
Development 22(23):3268-3281. 
44. Kinsella MG, Irvin C, Reidy MA, & Wight TN (2004) Removal of heparan sulfate by 
heparinase treatment inhibits FGF2-dependent smooth muscle cell proliferation in injured rat 
carotid arteries. Atherosclerosis 175(1):51-57. 
45. Sahni A & Francis CW (2004) Stimulation of endothelial cell proliferation by FGF2 in the 
presence of fibrinogen requires αvβ3. Blood 104(12):3635-3641. 
46. Murakami M, et al. (2008) The FGF system has a key role in regulating vascular integrity. 
The Journal of Clinical Investigation 118(10):3355-3366. 
47. Murakami M, et al. (2011) FGF-dependent regulation of VEGF receptor 2 expression in mice. 
The Journal of Clinical Investigation 121(7):2668-2678. 
48. Hosaka A, et al. (2004) Gelatin hydrogel microspheres enable pinpoint delivery of basic 
fibroblast growth factor for the development of functional collateral vessels. Circulation 
110(21):3322-3328. 
49. Takehara N, et al. (2008) Controlled delivery of basic fibroblast growth factor promotes 
human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial 
infarction. J Am Coll Cardiol 52(23):1858-1865. 
50. Laham RJ, et al. (2000) Intracoronary basic fibroblast growth factor (FGF2) in patients with 
severe ischemic heart disease: results of a Phase I open-label dose escalation study. J Am Coll 
Cardiol 36(7):2132-2139. 
51. Bush M, et al. (2001) Pharmacokinetics and pharmacodynamics of recombinant FGF2 in a 
phase I trial in coronary artery disease. The Journal of Clinical Pharmacology 41(4):378-385. 
52. Simons M, et al. (2002) Pharmacological treatment of coronary artery disease with 
recombinant fibroblast frowth factor-2. Circulation 105(7):788-793. 
53. Aviles RJ, Annex BH, & Lederman RJ (2003) Testing clinical therapeutic angiogenesis using 
basic fibroblast growth factor (FGF2). British Journal of Pharmacology 140(4):637-646. 
54. Lynch P, Lee T-C, Fallavollita JA, Canty JM, & Suzuki G (2007) Intracoronary administration 
of AdvFGF-5 (Fibroblast Growth Factor-5) ameliorates left ventricular dysfunction and prevents 
myocyte loss in swine with developing collaterals and ischemic cardiomyopathy. Circulation 
116(11 suppl):I-71-I-76. 
55. Henry TD, et al. (2007) Effects of Ad5FGF-4 in patients with angina: an analysis of pooled 
data from the AGENT-3 and AGENT-4 trials. Journal of the American College of Cardiology 
50(11):1038-1046. 
56. White AC, Lavine KJ, & Ornitz DM (2007) FGF9 and SHH regulate mesenchymal vegfa 
expression and development of the pulmonary capillary network. Development 134(20):3743-
3752. 
 111 
 
57. Frontini MJ, et al. (2011) Fibroblast growth factor 9 delivery during angiogenesis produces 
durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nat Biotech 29(5):421-
427. 
58. Shyu K-G, Manor O, Magner M, Yancopoulos GD, & Isner JM (1998) Direct intramuscular 
injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments 
revascularization in the rabbit ischemic hindlimb. Circulation 98(19):2081-2087. 
59. Tao Z, et al. (2011) Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and 
cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart. 
Proceedings of the National Academy of Sciences 108(5):2064-2069. 
60. Van Belle E, et al. (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth 
factor via Induction of vascular endothelial growth factor : the case for paracrine amplification of 
angiogenesis. Circulation 97(4):381-390. 
61. Tomita N, et al. (2003) Angiogenic property of hepatocyte growth factor is dependent on 
upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 107(10):1411-
1417. 
62. Ince H, et al. (2005) Prevention of left ventricular remodeling with granulocyte colony-
stimulating factor after acute myocardial infarction. Circulation 112(9 suppl):I-73-I-80. 
63. Hill JM & Bartunek J (2006) The end of granulocyte colony-stimulating factor in acute 
myocardial infarction? Circulation 113(16):1926-1928. 
64. Beohar N, Rapp J, Pandya S, & Losordo DW (2010) Rebuilding the damaged heart: the 
potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am Coll 
Cardiol 56(16):1287-1297. 
65. Pola R, et al. (2001) The morphogen Sonic hedgehog is an indirect angiogenic agent 
upregulating two families of angiogenic growth factors. Nat Med 7(6):706-711. 
66. Jakobsson L, et al. (2010) Endothelial cells dynamically compete for the tip cell position 
during angiogenic sprouting. Nat Cell Biol 12(10):943-953. 
67. Gore AV, et al. (2011) Rspo1/Wnt signaling promotes angiogenesis via Vegfc/Vegfr3. 
Development. 
68. Pellegrini L (2001) Role of heparan sulfate in fibroblast growth factor signalling: a structural 
view. Current Opinion in Structural Biology 11(5):629-634. 
69. Decher G (1997) Fuzzy nanoassemblies: toward layered polymeric multicomposites. 
Science 277(5330):1232-1237. 
70. Picart C, et al. (2002) Molecular basis for the explanation of the exponential growth of 
polyelectrolyte multilayers. Proc. Natl. Acad. Sci. U. S. A. 99(20):12531-12535. 
 112 
 
71. Capito RM, Azevedo HS, Velichko YS, Mata A, & Stupp SI (2008) Self-assembly of large 
and small molecules into hierarchically ordered sacs and membranes. Science 319(5871):1812-
1816. 
72. Pack DW, Hoffman AS, Pun S, & Stayton PS (2005) Design and development of polymers 
for gene delivery. Nat Rev Drug Discov 4(7):581-593. 
73. Jessel N, et al. (2006) Multiple and time-scheduled in situ DNA delivery mediated by β-
cyclodextrin embedded in a polyelectrolyte multilayer. Proceedings of the National Academy of 
Sciences 103(23):8618-8621. 
74. Wood KC, Chuang HF, Batten RD, Lynn DM, & Hammond PT (2006) Controlling interlayer 
diffusion to achieve sustained, multiagent delivery from layer-by-layer thin films. Proceedings of 
the National Academy of Sciences 103(27):10207-10212. 
75. Ono SS & Decher G (2006) Preparation of ultrathin self-standing polyelectrolyte multilayer 
membranes at physiological conditions using pH-responsive film segments as sacrificial layers. 
Nano Lett. 6(4):592-598. 
76. Dimitrova M, et al. (2008) Sustained delivery of siRNAs targeting viral infection by cell-
degradable multilayered polyelectrolyte films. Proceedings of the National Academy of Sciences 
105(42):16320-16325. 
77. Mazia D, Schatten G, & Sale W (1975) Adhesion of cells to surfaces coated with polylysine. 
Applications to electron microscopy. J. Cell Biol. 66(1):198-200. 
78. Jacobson BS & Branton D (1977) Plasma membrane: rapid isolation and exposure of the 
cytoplasmic surface by use of positively charged beads. Science 195(4275):302-304. 
79. Kinoshita T, Nachman RL, & Minick R (1979) Isolation of human platelet plasma 
membranes with polylysine beads. J. Cell Biol. 82(3):688-696. 
80. Yazynina EV, et al. (1999) Immunoassay Techniques for Detection of the Herbicide 
Simazine Based on Use of Oppositely Charged Water-Soluble Polyelectrolytes. Analytical 
Chemistry 71(16):3538-3543. 
81. Zeya HI & Spitznagel JK (1968) Arginine-rich proteins of polymophonuclear leukocyte 
lysosomes: antimicrobial specificity and biochemical heterogeneity. J. Exp. Med. 127(5):927-
941. 
82. Peterson PK, Gekker G, Shapiro R, Freiberg M, & Keane WF (1984) Polyamino acid 
enhancement of bacterial phagocytosis by human polymorphonuclear leukocytes and peritoneal 
macrophages. Infect. Immun. 43(2):561-566. 
83. Helander IM, Alakomi HL, LatvaKala K, & Koski P (1997) Polyethyleneimine is an effective 
permeabilizer of Gram-negative bacteria. Microbiology-Uk 143:3193-3199. 
84. Elferink JGR (1985) Cytolytic effect of polylysine on rabbit polymorphonuclear leukocytes. 
Inflammation 9(3):321-331. 
 113 
 
85. Elferink J & Deierkauf M (1989) Permeabilization and calcium-dependent activation of rabbit 
polymorphonuclear leukocytes by poly-L -arginine. Inflammation 13(3):285-294. 
86. Moghimi SM, et al. (2005) A two-stage poly(ethylenimine)-mediated cytotoxicity: implications 
for gene transfer/therapy. Mol Ther 11(6):990-995. 
87. Hunter AC (2006) Molecular hurdles in polyfectin design and mechanistic background to 
polycation induced cytotoxicity.  Advanced Drug Delivery Reviews 58(14):1523-1531. 
88. Choksakulnimitr S, Masuda S, Tokuda H, Takakura Y, & Hashida M (1995) In vitro 
cytotoxicity of macromolecules in different cell culture systems. Journal of Controlled Release 
34(3):233-241. 
89. Moreau E, Domurado M, Chapon P, Vert M, & Domurado D (2002) Biocompatibility of 
polycations: In vitro agglutination and lysis of red blood cells and in vivo toxicity. Journal of Drug 
Targeting 10(2):161-173. 
90. Fischer D, Li YX, Ahlemeyer B, Krieglstein J, & Kissel T (2003) In vitro cytotoxicity testing of 
polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 
24(7):1121-1131. 
91. Breunig M, Lungwitz U, Liebl R, & Goepferich A (2007) Breaking up the correlation between 
efficacy and toxicity for nonviral gene delivery. Proc. Natl. Acad. Sci. U. S. A. 104(36):14454-
14459. 
92. De Koker S, et al. (2007) In vivo cellular uptake, degradation, and biocompatibility of 
polyelectrolyte microcapsules. (Translated from English) Advanced Functional Materials 
17(18):3754-3763. 
93. Xiong MP, et al. (2007) PH-Responsive multi-PEGylated dual cationic nanoparticles enable 
charge modulations for safe gene delivery. Chemmedchem 2(9):1321-1327. 
94. Xiong MP, et al. (2007) Poly(aspartate-g-PEI800), a polyethylenimine analogue of low 
toxicity and high transfection efficiency for gene delivery. Biomaterials 28(32):4889-4900. 
95. Zern BJ, Chu H, Osunkoya AO, Gao J, & Wang Y (2011) A biocompatible arginine-based 
polycation. Advanced Functional Materials 21(3):434-440. 
96. Zern BJ, Chu H, & Wang Y (2010) Control growth factor release using a self-assembled 
[polycation:heparin] complex. PLoS ONE 5(6):e11017. 
97. Rick DL, Davis JW, Kram SL, Mang MN, & Lickly TD (1998) Biodegradation of an epoxy-
based thermoplastic polyester, poly(hydroxy ester ether) in a laboratory-scale compost system. 
Journal of Environmental Polymer Degradation 6(3):143-157. 
98. Ito N, Tonosaki S, Kudo H, Kameyama A, & Nishikubo T (2002) Synthesis and 
characterization of fluoropolymers by the polyaddition of bis(epoxide)s with dicarboxylic acids 
and diols. Journal of Polymer Science Part a-Polymer Chemistry 40(10):1395-1404. 
 114 
 
99. You Z, et al. (2010) A functionalizable polyester with free hydroxyl groups and tunable 
physiochemical and biological properties. Biomaterials 31(12):3129-3138. 
100. Gao J, et al. (2006) A neuroinductive biomaterial based on dopamine. Proceedings of the 
National Academy of Sciences 103(45):16681-16686. 
101. Boussif O, et al. (1995) A versatile vector for gene and oligonucleotide transfer into cells in 
culture and in vivo: polyethylenimine. Proceedings of the National Academy of Sciences 
92(16):7297-7301. 
102. Chu H, Gao J, Chen C-W, Huard J, & Wang Y (2011) Injectable fibroblast growth factor-2 
coacervate for persistent angiogenesis. Proceedings of the National Academy of Sciences 
108(33):13444-13449. 
103. Taipale, J. and J. KeskiOja (1997). "Growth factors in the extracellular matrix." Faseb 
Journal 11(1): 51-59. 
104. Macri, L., D. Silverstein, et al. (2007). "Growth factor binding to the pericellular matrix and 
its importance in tissue engineering." Advanced Drug Delivery Reviews 59(13): 1366-1381. 
105. Uebersax, L., H. P. Merkle, et al. (2009). "Biopolymer-Based Growth Factor Delivery for 
Tissue Repair: From Natural Concepts to Engineered Systems." Tissue Engineering Part B-
Reviews 15(3): 263-289. 
106. Whitelock, J. M., A. D. Murdoch, et al. (1996). "The degradation of human endothelial cell-
derived perlecan and release of bound basic fibroblast growth factor by stromelysin, 
collagenase, plasmin, and heparanases." Journal of Biological Chemistry 271(17): 10079-
10086. 
107. Raman, R., V. Sasisekharan, et al. (2005). "Structural insights into biological roles of 
protein-glycosaminoglycan interactions." Chemistry & Biology 12(3): 267-277. 
108. Gallagher, J. T. and J. E. Turnbull (1992). "Heparin-sulfate in the binding and activation of 
basix fibroblast growth-factor." Glycobiology 2(6): 523-528. 
109. Whitelock, J. M., J. Melrose, et al. (2008). "Diverse Cell Signaling Events Modulated by 
Perlecan." Biochemistry 47(43): 11174-11183. 
110. Saksela, O., D. Moscatelli, et al. (1988). "Endothelial cell-derived heparan sulfate binds 
basic fibroblast growth factor and protects it from proteolytic degradation." Journal of Cell 
Biology 107(2): 743-751. 
111 . Kreuger, J., D. Spillmann, et al. (2006). "Interactions between heparan sulfate and 
proteins: the concept of specificity." Journal of Cell Biology 174(3): 323-327. 
112. Gorsi, B. and S. E. Stringer (2007). "Tinkering with heparan sulfate sulfation to steer 
development." Trends in Cell Biology 17(4): 173-177. 
 115 
 
113. Capila, I. and R. J. Linhardt (2002). "Heparin - Protein interactions." Angewandte Chemie-
International Edition 41(3): 391-412. 
114. de Jong, J. G., R. A. Wevers, et al. (1989). "Dimethylmethylene blue-based 
spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for 
mucopolysaccharidoses." Clinical Chemistry 35(7): 1472-1477. 
115. DeBlois, C., M.-F. Côté, et al. (1994). "Heparin-fibroblast growth factorfibrin complex: in 
vitro and in vivo applications to collagen-based materials." Biomaterials 15(9): 665-672. 
116. Drogoz, A., L. David, et al. (2007). "Polyelectrolyte Complexes from Polysaccharides:  
Formation and Stoichiometry Monitoring." Langmuir 23(22): 10950-10958. 
117. Chen P-R, Chen M-H, Lin F-H, & Su W-Y (2005) Release characteristics and bioactivity of 
gelatin-tricalcium phosphate membranes covalently immobilized with nerve growth factors. 
Biomaterials 26(33):6579-6587. 
118. Lee MK & Lander AD (1991) Analysis of affinity and structural selectivity in the binding of 
proteins to glycosaminoglycans: development of a sensitive electrophoretic approach. 
Proceedings of the National Academy of Sciences of the United States of America 88(7):2768-
2772. 
119. Silva EA & Mooney DJ (2010) Effects of VEGF temporal and spatial presentation on 
angiogenesis. Biomaterials 31(6):1235-1241. 
120. Wenk E, et al. (2010) The use of sulfonated silk fibroin derivatives to control binding, 
delivery and potency of FGF2 in tissue regeneration. Biomaterials 31(6):1403-1413. 
121 Wood MD, Borschel GH, & Sakiyama-Elbert SE (2009) Controlled release of glial-derived 
neurotrophic factor from fibrin matrices containing an affinity-based delivery system. (Translated 
from English) J. Biomed. Mater. Res. Part A 89A(4):909-918 (in English). 
122 Kang CE, Tator CH, & Shoichet MS (2010) Poly(ethylene glycol) modification enhances 
penetration of fibroblast growth factor 2 to injured spinal cord tissue from an intrathecal delivery 
system. (Translated from English) J Control Release 144(1):25-31 (in English). 
123 Wang XQ, et al. (2009) Growth factor gradients via microsphere delivery in biopolymer 
scaffolds for osteochondral tissue engineering. (Translated from English) J. Control. Release 
134(2):81-90 (in English). 
124 Solorio LD, Fu AS, Hernandez-Irizarry R, & Alsberg E (2010) Chondrogenic differentiation 
of human mesenchymal stem cell aggregates via controlled release of TGF-beta 1 from 
incorporated polymer microspheres. J. Biomed. Mater. Res. Part A 92A(3):1139-1144. 
125 Wenk E, et al. (2010) The use of sulfonated silk fibroin derivatives to control binding, 
delivery and potency of FGF2 in tissue regeneration. Biomaterials 31(6):1403-1413. 
 116 
 
126 Tae G, Scatena M, Stayton PS, & Hoffman AS (2006) PEG-cross-linked heparin is an 
affinity hydrogel for sustained release of vascular endothelial growth factor. Journal of 
Biomaterials Science, Polymer Edition 17:187-197. 
127 Nilasaroya A, Poole-Warren LA, Whitelock JM, & Jo Martens P (2008) Structural and 
functional characterisation of poly(vinyl alcohol) and heparin hydrogels. Biomaterials 
29(35):4658-4664. 
128 Seal BL & Panitch A (2003) Physical Polymer Matrices Based on Affinity Interactions 
between Peptides and Polysaccharides. Biomacromolecules 4(6):1572-1582. 
129 Rajangam K, et al. (2006) Heparin Binding Nanostructures to Promote Growth of Blood 
Vessels. Nano Letters 6(9):2086-2090. 
130 Johnson PJ, Parker SR, & Sakiyama-Elbert SE (2009) Controlled release of neurotrophin-3 
from fibrin-based tissue engineering scaffolds enhances neural fiber sprouting following 
subacute spinal cord injury. Biotechnology and Bioengineering 104(6):1207-1214. 
131. Ingber DE (2002) Mechanical signalling and the cellular response to extracellular matrix in 
angiogenesis and cardiovascular physiology. Circ Res 91(10):877-887. 
132. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9(6):685-693 
133. Gupta R, Tongers J, & Losordo DW (2009) Human studies of angiogenic gene therapy. 
Circ Res 105(8):724-736. 
134. Sarkar K, Fox-Talbot K, Steenbergen C, Bosch-Marce M, & Semenza GL (2009) 
Adenoviral transfer of HIF-1 alpha enhances vascular responses to critical limb ischemia in 
diabetic mice. Proc Natl Acad Sci USA 106(44):18769-18774. 
135. van Royen N, Piek JJ, Schaper W, & Fulton WF (2009) A critical review of clinical 
arteriogenesis research. J Am Coll Cardiol 55(1):17-25. 
136. Dityatev A, Seidenbecher CI, & Schachner M (2010) Compartmentalization from the 
outside: the extracellular matrix and functional microdomains in the brain. Trends Neurosci 
33(11):503-512. 
137 . Klim JR, Li L, Wrighton PJ, Piekarczyk MS, & Kiessling LL (2010) A defined 
glycosaminoglycan-binding substratum for human pluripotent stem cells. Nat Meth 7(12):989-
994. 
138. Hacker U, Nybakken K, & Perrimon N (2005) Heparan sulphate proteoglycans: The sweet 
side of development. Nat Rev Mol Cell Biol 6(7):530-541. 
139. Sirko S, von Holst A, Wizenmann A, Götz M, & Faissner A (2007) Chondroitin sulfate 
glycosaminoglycans control proliferation, radial glia cell differentiation and neurogenesis in 
neural stem/progenitor cells. Development 134(15):2727-2738. 
 117 
 
140. Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 
4(7):528-539. 
141. Gotte M & Yip GW (2006) Heparanase, hyaluronan, and CD44 in cancers: a breast 
carcinoma perspective. Cancer Res 66(21):10233-10237. 
142. Casu B, Naggi A, & Torri G (2010) Heparin-derived heparan sulfate mimics to modulate 
heparan sulfate-protein interaction in inflammation and cancer. Matrix Biology 29(6):442-452. 
143. Aviezer D, et al. (1994) Differential structural requirements of heparin and heparan-sulfate 
proteoglycans that promote binding of basic fibroblast growth-factor to its receptor. J Biol Chem 
269(1):114-121. 
144. Moy FJ, et al. (1997) Properly oriented heparin-decasaccharide-induced dimers are the 
biologically active form of basic fibroblast growth factor. Biochemistry 36(16):4782-4791. 
145. Saksela O, Moscatelli D, Sommer A, & Rifkin DB (1988) Endothelial cell-derived heparan-
sulfate binds basic fibroblast growth-factor and protect it from proteolytic degradation. J Cell Biol 
107(2):743-751. 
146. Park JE, Keller GA, & Ferrara N (1993) Vascular endothelial growth-factor (VEGF) 
isoforms - differential deposition into the subepthelial extracellular-matrix and bioactivity of 
extracellular matrix-bound. Mol Biol Cell 4(12):1317-1326. 
147. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, & Simons M (1998) Therapeutic 
angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 
65(6):1540-1544. 
148. Sakiyama-Elbert SE & Hubbell JA (2000) Controlled release of nerve growth factor from a 
heparin-containing fibrin-based cell ingrowth matrix. J Control Release 69(1):149-158. 
149. Pellegrini L (2001) Role of heparan sulfate in fibroblast growth factor signalling: a structural 
view. Curr Opin Struct Biol 11(5):629-634. 
150. Zern BJ, Chu H, & Wang Y (2010) Control growth factor release using a self-assembled 
[polycation:heparin] complex. PLoS ONE 5(6):e11017. 
151. Chu H, Johnson NR, Mason NS, & Wang Y (2011) A [polycation:heparin] complex releases 
growth factors with enhanced bioactivity. J Control Release 150(2):157-163. 
152. Rusnati M, et al. (1999) Interaction of Fibroblast Growth Factor-2 (FGF2) with Free 
Gangliosides: Biochemical Characterization and Biological Consequences in Endothelial Cell 
Cultures. Mol. Biol. Cell 10(2):313-327. 
153. Crisan M, et al. (2008) A perivascular origin for mesenchymal stem cells in multiple human 
organs. Cell Stem Cell 3(3):301-313. 
154. Hanson EK & Ballantyne J (2010) A blue spectral shift of the hemoglobin Soret band 
correlates with the age (time since deposition) of dried bloodstains. PLoS ONE 5(9):e12830. 
 118 
 
155. Zheng B, et al. (2007) Prospective identification of myogenic endothelial cells in human 
skeletal muscle. Nat Biotech 25(9):1025-1034. 
156. Lafleur MA, Handsley MM, Knauper V, Murphy G, & Edwards DR (2002) Endothelial 
tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix 
metalloproteinases (MT-MMPs). J Cell Sci 115(17):3427-3438. 
157. Hosseinkhani H, Hosseinkhani M, Khademhosseini A, Kobayashi H, & Tabata Y (2006) 
Enhanced angiogenesis through controlled release of basic fibroblast growth factor from peptide 
amphiphile for tissue regeneration. Biomaterials 27(34):5836-5844. 
158. Richardson TP, Peters MC, Ennett AB, & Mooney DJ (2001) Polymeric system for dual 
growth factor delivery. Nat Biotech 19(11):1029-1034. 
159. Lindahl P, Johansson BR, Levéen P, & Betsholtz C (1997) Pericyte loss and 
microaneurysm formation in PDGF-B-deficient mice. Science 277(5323):242-245. 
160. Nehls V & Drenckhahn D (1991) Heterogeneity of microvascular pericytes for smooth 
muscle type alpha-actin. J Cell Biol 113(1):147-154. 
161. Laham RJ, et al. (1999) Local perivascular delivery of basic fibroblast growth factor in 
patients undergoing coronary bypass surgery : results of a phase I randomized, double-blind, 
placebo-controlled trial. Circulation 100(18):1865-1871. 
162. Sellke FW & Ruel M (2003) Vascular growth factors and angiogenesis in cardiac surgery. 
Ann Thorac Surg 75(2):S685-690. 
163 . Simons M, et al. (2002) Pharmacological treatment of coronary artery disease with 
recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. 
Circulation 105(7):788-793. 
164. Cao R, et al. (2003) Angiogenic synergism, vascular stability and improvement of hind-limb 
ischemia by a combination of PDGF-BB and FGF2. Nat Med 9(5):604-613. 
165. Saif J, et al. (2010) Combination of injectable multiple growth factor-releasing scaffolds and 
cell therapy as an advanced modality to enhance tissue neovascularization. Arterioscler Thromb 
Vasc Biol 30(10):1897-1904. 
166. ten Dijke P & Iwata KK (1989) Growth Factors For Wound Healing. Nat Biotech 7(8):793-
798. 
167. Gerard C. Blobe WPS (2000) Role of transforming growth factor β in human disease. New 
Engl J Med 342(18):1350-1358. 
168.  Lemmon MA & Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 
141(7):1117-1134. 
169. Cross MJ & Claesson-Welsh L (2001) FGF and VEGF function in angiogenesis: signalling 
pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22(4):201-207. 
 119 
 
170. Seghezzi G, et al. (1998) Fibroblast growth factor-2 (FGF2) induces vascular endothelial 
growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine 
mechanism contributing to angiogenesis. J Cell Biol 141(7):1659-1673. 
171. Zhang J, et al. (2009) Differential roles of PDGFR-α and PDGFR-β in angiogenesis and 
vessel stability. FASEB J 23(1):153-163. 
172. Millette E, et al. (2005) Platelet-derived growth factor-BB-induced human smooth muscle 
cell proliferation depends on basic FGF release and FGFR-1 activation. Circ Res 96(2):172-179. 
173  Payne TR, et al. (2007) A relationship between vascular endothelial growth factor, 
angiogenesis, and cardiac repair after muscle stem cell transplantation Into Ischemic Hearts. J 
Am Coll Cardiol 50(17):1677-1684. 
